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General Introduction
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1. Background
Currently, millions of people worldwide are affected by musculoskeletal diseases, which 
often lack optimal treatment, and result in concomitant long-term pain and physical 
disability. Other health problems of major public and treatment concern include com-
plicated bone fractures and intra-oral bone loss caused by periodontal disease. Unfor-
tunately, conventional treatment methods for bone healing have their limitations and do 
not always provide a successful solution for the above mentioned problems. Therefore, 
increasing efforts are focused on the development of novel therapeutic strategies to 
enhance bone healing and regeneration, and hence, to improve the quality of life for 
millions of people.
Traditional treatment methods for promoting bone healing primarily utilize bone grafts 
or synthetic materials to fill bone defects and to provide structural support. Bone au-
tografts are still considered the ‘gold standard’ for treating bone defects due to their 
osteogenicity and low risk of adverse immune response [1]. Allografts involve har-
vesting and processing bone from a different individual of the same species, which 
is subsequently transplanted into the patient. Xenografts, predominantly of bovine or 
porcine origin, are also used to treat bone defects. Disadvantages of using autografts 
for transplantations include limited availability of viable bone tissue, donor site morbi-
dity, and need for an additional surgical procedure, whereas the main concern related 
to the use of allografts and xenografts is the potential disease transmission. In cases 
where bone grafts from human or animal sources are not feasible (e.g. limited supply 
or insufficient bone volume available), synthetic graft materials (alloplasts) are used. In 
comparison with auto- and allografts, the limitations of these synthetic bone-replace-
ment materials comprise poor integration with the surrounding tissue, potential need 
for future retrieval or replacement, and inability to adapt to the dynamic environment. 
A guided tissue-regeneration (GTR) approach has offered some additional, beneficial 
bone healing options, since it employs materials that support natural bone-formation 
processes (e.g. hydroxyapatite, calcium phosphate, bioactive glasses, collagen, and 
biodegradable polymers) [2]. Nevertheless, the success of GTR is not always predict-
able, and this approach is limited in its application mainly to small bone defects, such 
as those caused by periodontal disease [3,4]. 
In view of the above mentioned, tissue engineering has emerged as a new therapeutic 
alternative to promote bone healing. In principle, tissue engineering is based on the 
understanding of tissue formation and regeneration, and aims to induce new functional 
tissues, rather than just implant new spare parts [5]. Bone tissue engineering aims to 
regenerate or repair bone tissue by development of bone graft substitutes, which are 
comparable or superior to autogenous bone and upon implantation will be replaced by 
patient’s own tissue. In general, tissue engineering approaches consist of three key 
elements: (1) matrix – also termed scaffold, combined with (2) cells and/or (3) biologi-
cally active molecules (e.g. growth factors, cell adhesion molecules) (Figure 1). Accord-
ing to the combination of key elements, bone tissue engineering approaches can be 
divided into two classes: (i) cell-based, and (ii) growth factors (GFs)-based, with the 
addition that many types of matrix/scaffold materials are currently commerically avail-
able, which are continuously being optimized to more closely mimic the properties of 
bone tissue. 
         Figure : Tissue engineering approach
Cell-based bone tissue engineering involves loading of osteogenic cells into the matrix/
scaffold. Osteogenic cells have to be harvested, isolated, expanded in vitro to higher 
passages and loaded/seeded to the scaffolds. From a bone tissue engineering per-
spective, this approach has evident advantages due to the high osteogenic potential of 
the cells. However, from a manufacturing and clinical point of view, it has a lot of limita-
tions which make the introduction of such a cell-based product to the clinical practice 
difficult and expensive. The major disadvantages involve the individual patient basis 
approach (cells are collected from the patient and transplanted into the same patient), 
invasive harvesting procedure (especially when bone-marrow mesenchymal stem cells 
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are collected), time and labour consuming in vitro cell expansion procedure, and the 
risk of disease transmission or cell infection (during cell culturing outside the body). All 
the above mentioned makes this cell-based approach currently not very appealing for 
standard or routine clinical application.
The alternative, a growth factor-based bone tissue engineering approach, seems to 
provide an easier and more cost-effective way to induce bone regeneration in patients. 
It includes the delivery of GFs known to regulate key aspects of bone metabolism di-
rectly to the defect sites, which upon release promote bone regeneration. The develop-
ment of recombinant DNA has enabled the production of large amounts of recombinant 
GFs (rh-GFs) for therapeutic use and has allowed their extensive investigation. GFs 
can be delivered alone (direct injection), through gene therapy or incorporated in a 
scaffold material. Preparation of GFs-loaded scaffolds is relatively simple and safe. 
Moreover, from a clinicial point of view it is a non-invasive approach and has universal 
application. On the basis of the available knowledge, GF-based bone tissue engineer-
ing appears to be the most promising and beneficial strategy for creation of the ideal 
bone graft substitute.
Bioactivation of surfaces with covalent bound peptides or with nanomechanically linked 
proteins (i.e. cell adhesion molecules) has appeared as another attractive strategy for 
bone tissue engineering. It is known that the first event that occurs during contact 
between a biomaterial (i.e. CaP) and biological fluids, is the adsorption of proteins on 
its surface. The attachment and adhesion of cells resulting in the future organization 
of the tissues depends on the nature of this adsorbed layer. Therefore, the tailoring or 
monitoring of peptide or protein immobilization represents one of the most challenging 
issues in the field of tissue engineering today.
In view of the current limitations of cell-based bone tissue engineering, only matrix-
based and GFs-based approaches are discussed in this thesis. The focus is placed on 
the development of a dedicated bone substitute using biologically active additives to 
stimulate bone regeneration.   
2. Calicum phosphate (CaP) ceramics 
Calcium phosphate (CaP) based ceramics are among the most frequently used materi-
als to facilitate bone healing [6]. Commercially available CaP biomaterials differ in origin 
(natural or synthetic), composition (hydroxyapatite, beta-tricalcium phosphate, biphasic 
CaP, etc.), physical form (particulates, blocks, cements, coatings on metal implants, 
composites with polymers), and physicochemical properties. In general, CaP biomate-
rials have outstanding properties that make them suitable for clinical application, such 
as similarity in composition to bone mineral, bioactivity (ability to directly bond to bone 
tissue), ability to promote cellular function and expression leading to formation of an 
uniquely strong bone-CaP biomaterial interface, and osteoconductivity. Osteoconduc-
tion, as defined by Davies et al. 1998 [7], is the process by which osteogenic cells mi-
grate to the surface of the scaffold through a fibrin clot, which is established right after 
the material implantation. In addition, CaP biomaterials are reported to be osteoinduc-
tive [8]. Osteoinduction is the process by which undifferentiated osteoprogenitor cells 
are committed to the osteogenic lineage and form osteoprogenitor cells [9]. It has been 
described that calcium phosphates can play an important role in the process of osteo-
induction. Numerous publications have reported already that a wide variety of different 
CaP ceramics can induce bone formation in various animal models [10-16]. The exact 
mechanism of osteoinduction by CaP materials is still unknown. It is hypothesized that 
this material-induced bone formation is the secondary reaction of bone-morphogenetic 
proteins (BMPs) concentrated in vivo on these materials [11]. On the other hand, the 
macro- and microstructure as well as chemical composition of the material has also 
been shown to play an important role in bone induction [17,18]. 
.. Biphasic CaP ceramic (BCP)
Biphasic calcium phosphate (BCP) consists of a mixture of hydroxyapatite (HA; 
Ca10(PO4) 6(OH)2) and beta-tricalcium phosphate (ß-TCP; Ca3(PO4)2) of varying HA/ 
ß-TCP ratios. BCP is obtained by sintering a synthetic or biologic calcium-deficient 
apatite (Ca/P ratio < 1.67) at a temperature of 700°C and above. Properties of BCP 
ceramics that define their clinical efficacy and can be modified according to clinical 
requirements include macroporosity, microporosity, compressive strength, bioactivity 
(in vitro and in vivo), dissolution, and osteoconductivity [6]. For example, the bioactivity 
can be controlled by manipulating the composition (HA/ß-TCP ratio), since it is known 
that ß-TCP has a higher dissolution rate than HA, which has been observed to affect 
the bone ingrowth [6]. Moreover, BCP can be osteoinductive, since it has a high affinity 
for proteins, including endogenous BMPs.  
Currently, BCP ceramics are recommended for use as an alternative or additive to 
autogenous bone for orthopedic and dental applications. They are available in the form 
of particulates, blocks, customized designs for specific applications, and as an inject-
able biomaterial in a polymer carrier [19]. Commercial biphasic calcium phosphate 
products include: Triosit® (Biomatlante Ltd, Nantes, France), MBCP® (Biomatlante Ltd), 
and Osteosynt® (Einco Biomaterial Co Bella Horizonte, Brazil), Straumann® Bone Ce-
ramic (Straumann AG, Basel, Switzerland). Various experimental studies have already 
demonstrated the potential of BCP ceramic as scaffold for bone tissue engineering 
[6,20,21]. 
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.. Injectable CaP cements
Injectable calcium phosphate (CaP) cements have been developed in the 90’s [22] 
to overcome disadvantages of prefabricated CaP materials, such as lack of shap-
ing and difficult delivery and maintenance of the prefabricated materials in the defect 
site. Currently, several injectable CaP cements are commercially available, such as 
Bone Source® (Stryker Leibinger, Kalamazoo, MI, USA), Norian® (Synthes, Oberdorf, 
Switzerland), alpha-BSM/Biobon® (Etex Corporation, Cambridge, MA, USA) and Cal-
cibon® (Biomet Merck, Darmstadt, Germany). These cements differ slightly in chemical 
composition, which results in differences regarding handling properties, setting time, 
strength and resorbability.
In general, CaP cements are known for their biocompatibility and osteoconductive 
properties [23]. The major advantage concerning clinical application is that CaP ce-
ments can be molded perfectly according to the defect dimensions, after which they 
set in situ. Injectable CaP cements consist of a powder containing one or more solid 
compounds of calcium phosphate salts and an aqueous cement liquid. Mixed in an ap-
propriate ratio, a paste is formed which sets at body temperature by entanglement of 
the crystals precipitating within the paste. After setting, the CaP crystals form a nanopo-
rous structure with pores smaller than 1 μm [22,24]. Although nano- (diameter < 1 μm) 
and microporosity (diameter < 10 μm) of the CaP cements are favourable for body fluid 
circulation [25], these do not allow bone ingrowth. Consequently, the ratio of cement 
surface area to cement volume is low and osteoclastic resorption rate is slow [26], re-
sulting in a slow degradation rate of the CaP cements. In an attempt to overcome these 
disadvantages, modified CaP cements have been developed [26,27]. Since it has been 
demonstrated that macroporosity (diameter >100 μm) [25] allows a scaffold to be colo-
nized by osteogenic cells and can increase early degradation, different methods to in-
troduce macroporosity into a CaP cement structure have been studied. For example, to 
generate macroporosity, NaHCO3 was added for production of CO2 gas in the cement 
[25,26,28]. Although in this way the degradation rate was enhanced and bone ingrowth 
was achieved, the compressive strength of the macroporous cement was greatly de-
creased. Another investigated method to generate porosity in the CaP cement involved 
the incorporation of PLGA microspheres into the scaffold [29] (Figure 2). 
Mechanical testing of this composite showed that it is stronger than previously described 
macroporous cement (i.e. with CO2 bubbles), but yet weaker than the cement without 
PLGA microspheres. The major advantage of the incorporation of PLGA microspheres 
into the CaP cement, besides the induced porosity after microsphere degradation to 
promote bone ingrowth and enhance CaP degradation, is that PLGA microspheres 
can be applied for the delivery of biologically active compounds with stimulatory effects 
on the bone healing process, such as BMP-2 [30]. Finally, the developed PLGA/CaP 
composite has demonstrated excellent biocompatibility at ectopic and orthotopic im-
plantation sites [29,31]. 
3. Biologically active additives for bone tissue regeneration 
The use of biologically active additives to stimulate bone healing is currently gaining 
clinical importance.
..Growth Factors
It is known that GFs play an essential role in the healing of injured tissue and act as 
regulators of the most basic cell functions, using endocrine, paracrine and intracrine 
mechanisms. Their mode of action is to bind to the extracellular domain of a target 
growth-factor receptor that, in turn, activates the intracellular signal-transduction path-
way [32-34]. These findings have led to a significant research effort aimed at testing 
different GFs and cytokines as therapeutic molecules for bone tissue repair and rege-
neration (Figure 3). 
               Figure : Growth factors for bone regeneration
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The most extensively studied bone growth stimulating factors are members of the trans-
forming growth factor-β (TGF-β) superfamily, comprising structurally and functionally 
related proteins, which regulate key aspects in bone metabolism [35]. This superfamily 
of molecules includes five TGF-β isoforms (TGF-β 1 to 5), the inhibins/activins, bone 
morphogenetic proteins (BMPs), and a number of distantly-related molecules [36]. 
TGF-β is one of the major GFs present in the extracellular matrix of bone tissue. It plays 
an important role in keeping the balance between the processes of bone resorption and 
subsequent bone formation. TGF-β1 appears to be the major isoform produced by hu-
man osteoblasts. In addition, TGF-β1 is highly expressed during fracture healing [37], 
suggesting that its role is not restricted to bone development and turnover, but extends 
to the process of bone repair. 
The primary role of TGF-β1 in bone formation seems to be the chemotaxis and mito-
genesis of osteoblast precursors. In addition, TGF-β1 affects osteoblast differentiation, 
matrix formation, and mineralization. 
However, there are several disadvantages concerning the application of TGF-β1. Un-
der certain conditions TGF-β1 can also stimulate osteoclast formation and function 
[38]. Consequently, treatment may induce both bone formation and resorption. Addi-
tionally, the half-life of TGF-β1 is too short (~2 min), implying the need for a matrix, 
which ensures a sustained release of the growth factor. Finally, TGF-β1 is involved 
in diverse functions outside the bone environment, suggesting that too high levels of 
TGF-β1 in the circulation or systemic administration of TGF-β1 might cause undesired 
side effects [39-42].
Despite the shortcomings of TGF-β1, positive effects on fracture healing and bone for-
mation predominate in all in vivo studies. Dosage, application mode and site, follow-up 
period, and animal species are parameters that influence the outcome of the therapy. 
An advantage in the use of TGF-β1 is the conservation of the amino acid sequence 
across species (interspecies homology), ensuring biological activity of recombinant 
human TGF-β1 in several animal models without facing the problem of antibody re-
sponses.
Another naturally occuring type of GFs that stimulate bone formation are BMPs. They 
were identified and cloned after the discovery that extracts from demineralized human 
bone matrix induce ectopic bone formation [36]. Currently, more than 20 members of 
the BMP family have been identified (BMP-2, BMP-4, BMP-7, BMP-8, etc.) [43]. BMP-2 
acts primarily as a differentiation factor for bone and cartilage precursor cells during 
osteogenesis and bone regeneration. BMP-2 and BMP-7 (also known as OP-1) have 
already been used in clinical trials and have proven their efficacy in the healing of criti-
cal-sized fibular defects and tibial non-unions in humans [44].
Other bone growth stimulating factors as present in bone are Insulin-like Growth Factor 
I and II (IGF-I and IGF-II). IGFs mediate the effects of systemic hormones (e.g. growth 
hormone), cytokines (e.g. interleukin-1α), and morphogens (e.g. BMPs) in bone forma-
tion and healing [45]. Fibroblast Growth Factors (FGFs) also play an important role in 
bone development and repair. FGFs are autocrine/paracrine regulators of bone forma-
tion, which stimulate chemotaxis, proliferation, and matrix synthesis of osteoblasts or 
osteoblast precursors, but do not directly promote osteoblast differentiation [45]. 
GFs that stimulate angiogenesis, including Vascular Endothelial Growth Factor (VEGF) 
and Platelet Derived Growth Factor (PDGF) are also very relevant for bone repair and 
regeneration. VEGF plays an important role in the regulation of the interaction between 
osteogenesis and angiogenesis. PDGF is supposed to play a role in the migration of 
mesenchymal stem cells (MSCs) to the wound healing sites. 
The GFs discussed above have been extensively investigated, since the recombinant 
DNA technology has enabled their availability in large quantities at lower costs. Con-
ventional delivery methods for recombinant GFs in bone tissue engineering employ 
direct injection of a single GF in the defect site [46]. Due to the short half-life of many 
recombinant GFs, usually very high doses are required to achieve a therapeutic effect 
[46,47]. A disadvantage of this delivery approach is that an initial high concentration of 
the growth factor is provided (burst-release), while maintenance of a much lower level 
for an appropriate period of time can be much more effective. Such a sustained deli-
very mimics also better the natural physiological process of bone healing. In addition, 
under phsyiological conditions tissue formation and reparative processes rely not only 
on just one single GF, but on several GFs that work in concert to form functional tissue. 
To achieve this, an engineering strategy can be followed by designing release systems 
that are able to deliver low doses of various relevant GFs over the course of several 
weeks. On the other hand, use can also be made of natural alternative systems, like 
platelet-rich plasma (PRP).  
.. Platelet-rich plasma (PRP)
Platelet-rich plasma (PRP) is defined as an “autologous concentration of platelets in 
a small volume of plasma”[48]. It is considered to be a rich source of autologous GFs, 
due to the many GFs present in the platelets’ alpha- (α-) granules. In vitro studies have 
demonstrated clearly, that GFs derived from platelets stimulate the proliferation of both 
human trabecular bone cells [49] and human osteoblast-like cells [50]. The following 
GFs are reported to be present in platelets α-granules and released upon platelets’ 
activation: Platelet Derived Growth Factor (PDGF) in its three isoforms (αα, ββ, αβ), 
Transforming Growth Factor (TGF) in its two isoforms (β1 and β2), Vascular Endothelial 
Growth Factor (VEGF), Epithelial Growth Factor (EGF), Insulin-like Growth Factor -1 
(IGF-1), basic Fibroblast Growth Factor (bFGF), as well as three blood proteins known 
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to act as cell adhesion molecules for osteoconduction (i.e. fibrin, fibronectin and vitro-
nectin) [51-53]. 
The active secretion of GFs from platelets begins within 10 min after the regular blood 
clotting process has started. More than 95% of the presynthesized GFs in the platelets 
α-granules are secreted within 1 hour (Figure 4).
This release is thought to accentuate the bone reparative response. After the initial 
burst release of PRP-related GFs, platelets synthesize and secrete additional GFs for 
the remaining 10 days of their life span. Afterwards, macrophages attracted to the bony 
wound site take over and secrete additional GFs to regulate and continue bone rege-
neration.
Briefly, the basic hypothesis of PRP addition to bone grafts is that high concentrations 
of platelets in a bony wound will increase the local concentration of GFs and subse-
quently enhance the initial bone healing response. In a later stage, the direct influence 
of PRP will fade away and physiological mechanisms of bone repair will continue to 
work on an accelerated level [54].
For bone tissue engineering PRP can be combined with different types of scaffolds, 
such as mineral and organic bone matrices [52,55]. One potential benefit of this com-
bination is the improved handling and adaptation of the matrix to the injured tissue be-
cause the fibrin acts as a biological glue to hold together the matrix particles. Moreover, 
early vascular invasion is a key factor in bone allograft or xenograft incorporation, which 
reduces complications related to slow and incomplete integration. For example, Aghal-
loo et al. evaluated deproteinized bone mineral of bovine origin Bio-oss® (Geistlich, 
Wolhusen/Switzerland) with and without PRP in rabbit cranial defects and observed 
significant histomorphometric improvement in bone formation when PRP was applied 
[56]. Recently, beneficial effects of treating intrabony periodontal defects with PRP 
combined with different kind of bone substitutes in controlled clinical trials have been 
reported [56-58]. However, there are controversies in the literature regarding the poten-
tial benefits of PRP as an adjunct to osseous regeneration. While some authours have 
reported significant improvements in tissue healing and bone formation using PRP 
[53,59,60], others failed to observe improvement [61-63]. So far the best results for 
bone regeneration are reported when PRP is added to bone grafting material [53]. An 
explanation can be that only autogenous grafts have receptors to bind GFs released by 
PRP upon platelets activation [53]. Nevertheless, since favorable bone formation has 
also been reported when PRP has been combined with bone substitutes, its application 
together with biomaterials should be further examined and developed. Moreover, it has 
to be emphasized that upon its first discovery PRP has been directly introduced into the 
clinic and its exact mechanisms of action still remain unclear. 
The feasibility of PRP as scaffold for cell-based bone tissue engineering has also been 
explored. In most of the approaches mesenchymal stem cells (MSC) have been com-
bined with PRP. MSC-PRP mixture has the advantage of being simultaneously osteo-
genic, osteoconductive and osteoinductive due to the bone-forming capacity of MSCs 
and the presence of secreted GFs in the three-dimensional fibrin scaffold. For example, 
Ito et al. studied the potential of a MSC-PRP mixture compared with autogenous bone, 
Bio-Oss® and PRP, and found out that this mixture provided greater bone maturation 
and early-stage bone regeneration compared to the rest of the treatments [64]. 
Concerning the technique for producing PRP, PRP is derived from the whole blood 
of the patient through gradient density centrifugation. The technique involves use of 
a medical cell separator or a commercially available platelet-concentrating separator, 
such as the Smart PreP system (Harvest Autologous Hemobiologics, Norwell, Mas-
sachusetts, USA), PCCS (3i Implant innovations, Palm Beach Gardens, Florida), or 
Curasan PRP kit (Curasan, Pharma Gmbh AG, Lindigstrab, Germany). These devices 
separate and concentrate platelets from small amounts of autologous blood, drawn 
preoperatively. To obtain PRP, two separate centrifugations, called spins, are required. 
The first spin, known as the separation spin, separates the red blood cells from the 
rest of the whole blood (white blood cells, platelets and plasma) (Figure 5-2). This is 
followed by a concentration spin, which separates the platelets, white blood cells, and 
a small number of residual red blood cells from the plasma (Figure 5-4). 
Figure : PRP preparation technique (Smart PreP system) (Internet image, Harvest technologies)
This two-spin procedure results in PRP, which consists of a high concentration of plate-
lets (4- to 5-fold increase over baseline platelet number in whole blood) and a native 
concentration of fibrinogen [65]. Prior to clinical application, the platelet concentrate is 
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activated (by the addition of thrombin and calcium chloride), which causes start of the 
clotting process. This in turn results in degranulation of the platelets’ α-granules and 
release of the GFs.
.. Cell adhesion molecules
Besides GFs, cell adhesion molecules (or extracellular-matrix molecules) have also 
been explored in the field of bone tissue engineering. It is known that certain peptides, 
(or extracellular-matrix molecules) such as laminin and fibronectin, available in serum, 
can enhance cellular attachment of various cell types, including bone cells, to synthetic 
surfaces (biomaterials) and hence, increase the bioactivity of these materials [66, 67]. 
This effect is mediated through integrin receptors on the cell surface. There are several 
types of integrins that are cell and tissue specific and bind to specific amino acid se-
quences [68,69]. Osteoprogenitor cells carry integrin receptors, that bind to collagen and 
to certain peptides that contain a sequence of three amino acids (Arg-Gly-Asp), called 
RGD peptides. A selective activation of these receptors can preferably make bone form-
ing cells become attached to the implant surface and thereby increase bone anchorage 
particularly in areas where the biological activity of the adjacent bone may be deficient 
[70]. Therefore, coating of biomaterials with RGDs offers an attractive strategy for con-
trolling the cell-material interface and achieving a bioactive implant.
Other already clinically applied cell adhesion proteins, which are considered to enhance 
bone regeneration are ‘enamel matrix derivates’ (EMDs). EMDs are the major compo-
nent of commercially available Emdogain® (Biora AB, Malmö, Sweden), which is ap-
proved for the treatment of periodontal defects. Emdogain® is a purified acidic extract of 
developing embryonic enamel derived from six-months-old piglets [71] (Figure 6). 
              a)                     b)
Figure : Emdogain® : a) SEM; b) clinical formulation  (Internet image, Straumann® Emdogain)
It is available in two formulations: a lyophilized form to be dissolved in an aqueous 
solution of PGA (propylene glycol alginate) prior to use and in a pre-mixed PGA-gel for-
mulation. Both formulations contain 30 mg EMD protein/ml PGA gel, and are reported 
to have the same effects [72]. Due to the highly conserved structure and function of 
enamel matrix proteins among mammalian species and the exposure to these proteins 
in early childhood during tooth development, Emdogain®, although being of porcine 
origin, is considered “self-made” when encountered in the human body. Therefore, it 
can promote periodontal regeneration in humans without triggering allergic or immune 
responses or other undesirable reactions. 
The major fraction of EMDs is composed of amelogenin, which is a cell-adhesion ma-
trix-bound protein [73]. It is supposed to be active in epithelial-mesenchymal signalling 
and may also have direct signalling activities on cementoblasts and thus, on osteo-
blasts (73). Amelogenin, together with enamelin, sheathlin and 2 enzymes (MMP-20 
and EMPS1) are present in Emdogain® and define its action, thereby the main biologi-
cal effect is attributed to amelogenin.
In general, EMDs are supposed to induce mesenchymal cells to mimic the events that 
occur during root development and thus to stimulate regeneration of periodontal tis-
sues, i.e. cementum, periodontal ligament, and bone. The ability of EMDs to enhance 
bone formation in a nude mouse model were defined as osteopromotive [74] and were 
suggested to be due to the enhancement of the osteoinductive potential of the graft 
material by EMDs. However, it was also hypothesized that EMDs show osteopromotive 
characteristics because of the presence of bone growth stimulating factors [75], and 
a threshold concentration of EMDs is required to evoke an effect [76]. Although early 
immunoassay studies could not identify the presence of growth factors in EMDs [77], 
nominal levels of TGF- β1 [78] as well as BMP-2 and BMP-4 have been currently de-
tected in an osteoinductive fraction of enamel extracts [79]. 
4. Objectives of the thesis
The present research is focused on the application of different biologically active addi-
tives for bone tissue regeneration. The final goal is to acquire more information about 
the efficacy of their bone regenerative properties and to develop a dedicated bone 
substitute that could be used in the clinic. The specific aims of this thesis are:
1. To summarize data available in the literature and provide evidence for clinical ap-
plication of PRP in oral-maxillofacial bone regeneration;
2. To investigate the early effect of PRP on bone formation in combination with an os-
teoconductive material in a rat model;
3. To investigate the late effect of PRP on bone formation in combination with an osteo-
conductive material in a rat model;
4. To compare the effect of rat, goat and human PRP in combination with allograft and 
autograft in an immunodeficient rat model;
5. To examine the bone augmentation properties of TGF-ß1 incorporated in an inject-
able PLGA/CaP composite in a rat model;
6. To evaluate the bone regenerative properties of EMD at osseous and non-osseous 
sites in a rat model.
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Introduction
Platelet-rich plasma (PRP) is defined as an “autologous concentration of platelets in a 
small volume of plasma” (Marx 2004) and is considered to be a rich source of autologous 
growth factors. It was first introduced in 1998 by Marx and coworkers, in combination 
with autogenous bone grafts for reconstruction of mandibular defects (Marx et. al 1998). 
Their study showed that the addition of PRP to bone grafts resulted in a faster radio-
graphic maturation rate and higher bone density than bone grafts alone. Since then, the 
effect of PRP on bone regeneration has been extensively investigated. In the field of 
dentistry PRP has been used in different clinical procedures (i.e. sinus floor elevation, 
alveolar ridge augmentation, mandibular reconstruction, maxillary cleft repair, treatment 
of periodontal defects and treatment of extraction sockets), where it has been applied 
alone or in addition to autogenous bone, anorganic bone mineral and organic bone sub-
stitues. Many papers reported positive effects of PRP on bone formation (Whitman et al. 
1997, Kassolis et al. 2000, Camargo et al. 2002, Lekovic et al. 2003, Fennis et al. 2004, 
Nikolidakis et al. 2006). On the other hand, limited or no beneficial effect has also been 
shown (Froum et al. 2002, Monov et al. 2005, Raghoebar et al. 2005, Thor et al. 2005, 
Plachokova et al. 2006).  
The contribution of PRP to the bone healing process is thought to be based on the 
growth factors (GFs) stored in it. The following GFs are reported to be present in PRP: 
Platelet Derived Growth Factor (PDGF), Transforming Growth Factors-beta (TGF-ß), 
Vascular Endothelial Growth Factor (VEGF), Epithelial Growth Factor (EGF), Insulin 
Growth Factor-1 (IGF-1), basic Fibroblast Growth Factor (bFGF), as well as three blood 
proteins known to act as cell adhesion molecules for osteoconduction: (i.e. fibrin, fibro-
nectin and vitronectin) (Tozum& Demiralp 2003, Sanchez et al. 2003). Therefore, PRP 
may influence bone formation through a variety of pathways.
The basic hypothesis of PRP addition to bone grafts is that high concentrations of plate-
lets in a bony wound will increase the local concentration of secreted growth factors and 
subsequently enhance initial bone healing response. Later on, the direct influence of 
PRP will fade away and physiological mechanisms of bone repair will continue to work 
on an accelerated level (Jakse et al. 2003). 
Currently, there is a lack of scientific evidence in the dental literature in favour of or 
against the clinical use of PRP for bone regeneration. Several reviews on the application 
of PRP in dentistry have been published (Schilephake 2002, Soffer et al. 2003, Tozum& 
Demiralp 2003, Sanchez et al. 2003, Marx 2004, Freymiller & Aghaloo 2004, Grageda 
2004), but none of them followed a systematic approach. The aim of this systematic 
review is to determine and to structurally analyze the reported effects of PRP on bone 
regeneration in humans. For this purpose all clinical PRP applications in the field of 
dentistry will be considered. 
Materials and Methods
A protocol was set-up prior to commencing the review, including agreements on search 
strategy, study inclusion criteria, data extraction, and statistical analysis.
The literature was searched for references published up to June 2006 in MEDLINE and 
Cochrane Central Register of Controlled Trial databases. Three search terms - “plate-
let-rich plasma”, “bone regeneration” and “dentistry”- were used together with their all 
known synonyms.“Bone regeneration” and “dentistry” were applied as MeSH terms, 
all the others as free-text terms. As a result, the following combinations were made: 
“platelet rich plasma” OR “platelet-rich plasma” OR “PRP” OR “autologous platelet gel” 
OR “plasma-rich growth factors” OR “autologous platelet concentrate” OR “platelet 
concentrates” AND “bone regeneration” OR “bone healing” AND “dentistry”. Abstracts 
of these references were read and controlled clinical trials meeting specific criteria were 
identified. Studies were included only if these (a) reported treatment outcomes (either 
by clinical, radiographic or/and histological measures) of PRP and controls on bone 
healing, (b) included at least 5 patients, and (c) had a follow-up of at least 3 months. 
Only papers written in English were considered. Papers not meeting all criteria were 
excluded. If no abstract was available in the databases, the abstract of the printed ar-
ticle was used. If title and abstract did not provide sufficient information to assess the 
eligibility of the paper, the full report was obtained as well. In addition, reference lists of 
previous published reviews were searched to detect additional studies. The search was 
carried out by two readers (A.P. & D.N.) independently. Disagreements were resolved 
by discussion.
In the following step the selected articles were printed and once again assessed by the 
two readers for the same inclusion criteria. For this purpose only Materials and Meth-
ods, and Results sections were used. Reference lists of papers included were checked 
by hand and cross-matched with the original list of references in order to detect addi-
tional studies that met the inclusion criteria. Relevant data (e.g. study design, patients’ 
characteristics, methods of PRP preparation, clinical outcomes, evaluation period) were 
extracted. Furthermore, study quality was assessed according to key quality compo-
nents of controlled trials. Definitions for the quality assessment items were derived from 
two guidelines for systematic reviews (Cochrane Reviewers’ Handbook, 2001 and NHS 
Centre for Reviews and Dissemination, 2001, and Montenegro et al. 2002). 
Cohen’s Kappa-coefficient was used as a measure of agreement between the two 
readers in each step. Outcomes of the interventions in each study were compared. For 
this purpose Means and Standard Deviations (SD) or Standard Errors (SEM) drawn 
from each study were used to calculate Confidence Intervals (CI).  The statistical analy-
sis was performed by means of a commercially software program (SPSS for Windows 
version 12.0, SPSS Inc, Chicago, IL, USA).
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Results
The MEDLINE and Cochrane search resulted in 108 hits. From assessing the titles 
and abstracts, ninety-one were excluded (inter-reader agreement k = 0.89 ± 0.06) and 
finally, 17 articles were accepted for further analysis. One paper appeared to be unre-
trievable (Simon et al. 2004) resulting in sixteen articles remained to be read. Reading 
Materials and Methods and Results sections of the articles revealed 9 papers fulfilling 
the inclusion criteria (inter-reader agreement k = 1). Seven studies were excluded in 
this step: three of them were reviews and four had no control group. The hand search 
did not reveal additional studies to be included. All papers selected in the first selection 
step and the studies remaining after the second selection are presented in Table 1. 
Table 1: Papers selected after first selection (in alphabetical order, n=17), papers remaining after second selection 
are presented in italics (n=10)
Table 2 shows the extracted data according to different treatment modalities. A sub-
stantial heterogeneity in the studies existed with regards to patient populations, study 
designs, PRP preparation techniques, outcome measures and observation periods. 
The studies that reported similar outcome measures (i.e. clinical attachment level and 
percentage of new bone formation) were compared using the calculated Confidence 
Intervals (CI): Figures 1 and 2. PRP treatments of periodontal defects were significantly 
more effective compared to their controls in two studies (Okuda et al. 2005, Sammar-
tino et al. 2003). In the study of Hanna et al. the difference was very small and there 
was CIs overlap. 
Table 2: Extracted data according to different treatment modalities
Figure 1: Comparison of the Mean values and 95% Confidence Intervals for test and control groups of the selected 
studies performed for treatment of periodontal defects. The results of ΔCAL in mm are presented. The means of the 
controls were set on 0. Plus (+) values show favorable effect of PRP.
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Figure 2: Comparison of the Mean values and 95% Confidence Intervals for test and control groups of the selected 
studies performed for sinus elevation. The results of bone formation in % are presented. The means of the controls 
were set on 0. Plus (+) values show favorable effect of PRP.
With respect to the use of PRP in sinus elevation, one study (Raghoebar et al. 2005) re-
ported no difference compared to the control. The study of Wiltfang et al. 2003 reported 
a positive effect of 9%, however there was a substantial overlap in the CIs. Overall, no 
significant difference in the treatment outcome was observed between sinus elevation 
procedures with and without PRP.
Table 3 presents the outcomes of the study quality assessment (inter-reader agreement 
k = 0.90 ± 0.04). Overall, the majority of them do not meet current recommendations 
on study quality related to sample size calculation, randomization methods, allocation 
concealment, examiner blinding, validity of statistical methods and validity of outcomes 
and estimation.
Table 3:  Quality assessment of selected studies (n=9)
Discussion
This systematic review aimed to assess the available scientific evidence for applying 
PRP for bone regeneration in all fields of dentistry. The inter-reader agreements for 
inclusion of papers and quality assessment are unusually high (i.e. first step k = 0.89 ± 
0.06, second step k = 1, quality assessment k = 0.90 ± 0.04) most probably because 
both readers are well acquainted with the subject of PRP (Plachokova et al. 2006, 
Nikolidakis et al. 2006). 
Unfortunately, no statistical analysis of the data was possible due to the heterogeneity 
of the studies. However, the present study is considered a qualitative systematic review 
since rigorous methods for outcome assessment were applied (Sutherland 2004). At 
the same time a risk of publication bias has to be mentioned, since English language 
was used as a limit by the literature search. Moreover, unpublished data, as well as 
commercial interests in the studies were not explored.
An attempt was made to compare results from the studies that used similar outcome 
measures by adding Confidence Intervals to the data presented in the original papers 
(Figure 1 and Figure 2). On one hand, it was not allowed to pool these data because 
of different follow-up periods. On the other hand, the similar and objective presentation 
of the measured outcomes from the different studies enabled a relative comparison. 
Differences in treatment effects for periodontal defects in terms of clinical attachment 
level (CAL) were significant, the mean differences ranging from 0.8 to 3.2 mm, how-
ever, the differences in the CI in two out of tree studies appeared to be small (Hanna et 
al. and Okuda et al). An explanation for the superiour results of Sammartino et al. 2005 
(above the rest of the studies) could be the shorter evaluation period used (3 months 
versus 6 and 12 months). PRP is supposed to exert its effect on the early stages of 
bone formation, accelerating the bone healing process, therefore it could be specu-
lated that at later time points this effect diminishes or does not exist any more. Besides 
that, PRP in the study of Sammartino was used to treat periodontal defects caused by 
the complications of mesioangular impacted mandibular third molar, whereas in the 
studies of Hanna et al. and Okuda et al. PRP was applied in defects caused by peri-
odontal disease. In addition, the age effect of the patients enrolled in the studies, as a 
factor influencing the treatment outcomes, could not be excluded. In the study of Sam-
martino patients’ ages ranged between 21 and 26, whereas in Hanna et al. between 35 
and 75 years. The mean age reported by Okuda et al. was 55.5 ± 8.2.
Another explanation for the overall positive effects reported by the periodontal studies 
could be the methods of assessment used (CAL and PD measurements). It is known 
that besides to bone formation, gain in CAL is due to formation of a connective tissue 
fibers and long junctional epithelium. Since it is claimed that PRP has also stimulatory 
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effect on fibroblasts (Marx et al.1998), it could be the PRP enhanced connective tissue 
proliferation that caused the positive changes in the outcome measures. Clinically it 
is not possible to discern how much of the gain in CAL is due to bone formation and 
how much to connective tissue ingrowth. Only histological evaluation can provide this 
information. Unfortunately, re-entry procedures to obtain histological samples are not a 
routine practice, especially when periodontal regeneration is aimed/perceived. In this 
regard, Zybutz et al. 2000 compared clinical (PD and CAL) and radiologic measure-
ments of intrabony defects to direct bone measurements during surgical procedure, 
and concluded that probing attachment level measurements (CAL) are accurate meth-
ods of assessing bone level and can be reliably used to assess bone level changes 
after treatment (Zybutz et al. 2000). This finding may validate the conclusions of the 
above-mentioned studies, which results are based only on the changes of CAL and PD 
over time. However, it has to be emphasized that histological evaluations are needed 
to corroborate the bone regenerative effect of PRP.
In view of the sinus elevation procedures, the reported effects of PRP (compared to 
their controls) were less than 10%, Moreover, there was a wide variety in outcome, 
which is demonstrated by the large Confidence Intervals (> 10%). Consequently, the 
evidence for a beneficial effect of PRP in sinus elevation is considered to be weak. This 
corroborates the conclusions of the review of Boyapati and Wang (Boyapati & Wang 
2006). Based on animal and human studies they concluded that the additional use of 
PRP in sinus augmentation could not be recommended.
Overall, the majority of the reviewed studies reported positive effect of PRP for bone re-
generation. However, the quality assessment of these studies, judged by their reports, 
revealed that most of them do not meet current recommendations on study quality. 
Study designs, randomization methods, concealments of the allocation sequence and 
blinding of examiners could not be judged adequately. In some studies the validity of 
outcomes and estimation was found unclear or even inadequate. If these methods are 
not implied or properly executed in the actual study conduct, outcomes of these trials 
could be biased. Inadequate or unclear methods were found to exaggerate the treat-
ment effect compared with adequate methods (Juni et al. 2001; Colditz et al. 1989). In 
view of the above mentioned, the data provided by poor quality studies as judged by 
their publications, can not be used as evidence. To increase evidence, better reporting 
of clinical trials on PRP is required, and the CONSORT statement (Moher et al. 2001b) 
is suggested as a helpful guide for improving study quality.
In this review a substantial heterogeneity among the studies was observed. One of the 
reasons is the difference in protocols as used for PRP production. Some studies used 
commercially available platelet-concentrating separators (FDA approved and/or Euro-
pean recognized) for PRP production, others used general-purpose cell separators. It 
has been claimed that the latter can be acceptable only when a standardized, two step 
spin procedure is followed. Single-spin machines have been reported to be incapable 
of separating and concentrating platelets to a therapeutic level (Marx & Garg 2005). 
Some of the included studies using the non-FDA-approved devices failed to provide 
a detailed description of the protocol for PRP production. In general, preferably this 
description should include information about the cell-separator used (name company, 
country,) centrifugation steps (rotations per minute, g/minutes), amount of blood col-
lected preoperatively, baseline number of platelets in the collected blood, amount of 
PRP obtained, number of platelets in the obtained PRP (increase above baseline). In 
addition, the use of coagulation promoters (doses, mixing ratio to PRP) is considered 
indispensable information. In the current systematic review papers were not excluded 
for this reason since the ommissions in the descriptions were only limited. However, the 
inclusion of above-mentioned parameters has to be recommended. 
In summary, evidence was found for the use of PRP in periodontal defects. The evi-
dence available in the dental literature for beneficial effects in sinus elevation is weak. 
No conclusions can be drawn about PRP for other applications in dentistry.
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Introduction
In order to create a bone graft, which is comparable or superior to natural bone, al-
lografts are combined with osteoinductive substances, such as recombinant growth 
factors (GFs) (Jansen et al. 2005). A disadvantage of the recombinant GFs is that they 
are expensive. In view of this, platelet-rich plasma (PRP), as a rich source of autolo-
gous growth factors, is considered to be an alternative approach (Marx et al. 1998). 
The basic hypothesis of the addition of PRP to bone grafts is that a high concentration 
of platelets in a bone defect will increase the local concentration of secreted GFs and 
subsequently enhance initial bone regeneration (Marx et al. 1998). After a few days, the 
direct influence of the administered PRP will fade away and physiological mechanisms 
of bone repair continue to work on an accelerated level (Jakse et al. 2003). The follow-
ing GFs are reported to be present in PRP: Platelet Derived Growth Factor in its three 
isoforms (PDGFαα, ßß, αß), Transforming Growth Factors-beta (TGF-ß1 and TGF-ß2), 
Vascular Endothelial Growth Factor (VEGF) and Epithelial Growth Factor (EGF), as 
well as three blood proteins known to act as cell adhesion molecules for osteoconduc-
tion: i.e. fibrin, fibronectin and vitronectin (Marx et al. 1998; Marx 2004). According to 
some authors PRP is also a storage vehicle for basic Fibroblast Growth Factor (bFGF), 
Insulin Growth Factor-1 (IGF-1), Platelet Factor-4 (PF-4), and interleukin-1 (Aghaloo et 
al. 2002; Tozum & Demiralp 2003; Sanchez et al. 2003). All this implies that PRP might 
influence bone formation through a variety of pathways.
Calcium phosphate ceramics, e.g. hydroxyapatite (HA) and tricalcium phosphate (TCP) 
are frequently used for bone reconstruction, because of their close resemblance to the 
bone mineral phase (Dalcusi et al. 2003; El-Ghannan 2005). Both HA and TCP are 
biocompatible and osteoconductive, but at the same time have their disadvantages. 
Previous studies revealed that HA particles are a good bone filler for new bone forma-
tion, but they are poorly resorbable. On the other hand, TCP tends to resorb unpredict-
ably in biologic fluids and in a variety of solvents (Dalcusi et al. 2003). The fabrication 
of biphasic calcium phosphate ceramic (BCP) made it possible to control the resorb-
ability of the material and at the same time to maintain its osteoconductive property. In 
a previous case report it was shown that a ratio of 60% HA to 40% β-TCP provides a 
bone conductive surface (Ellinger et al. 1986). This was confirmed in a previous study 
of our group using dense HA/β-TCP (60%/40%) particles, with a size of 300 - 500 μm 
to fill cranial defects in rats (Plachokova et al. 2006). At the same time we hypothesized 
in our previous study that such particles could be a good delivery vehicle for the growth 
factors present in PRP. Unfortunately, after an implantation period of 4 weeks no effect 
at all of PRP on bone formation was demonstrated, irrespective whether PRP was ap-
plied in form of a liquid or gel (Plachokova et al. 2006). However, due to the fact that 
the mitogenic properties of the cytokines present in PRP act during the first 1-2 days 
and the life span of the platelet itself is less than 5 days, a substantial impact of PRP 
on bone regeneration might only be observed during the early stages of bone healing 
(Malaval et al. 1994; Kessler et al. 2000). Moreover, the rat cranial defects were almost 
completely closed after 4 weeks, which could have prevented PRP to demonstrate 
its positive influence. Therefore, we decided to investigate the effect of PRP on bone 
regeneration for an implantation time of 1 and 2 weeks. 
In summary, in this study we hypothesize that PRP exerts its beneficial effect on bone 
regeneration within the first and second week after application in a bone defect com-
bined with an osteoconductive material. 
Materials and Methods 
Bone fillers
Dense HA/β-TCP (60%/40%) particles with a size of 300-500 μm (Camceram, CAM Im-
plants, Leiden BV, the Netherlands) were used as synthetic bone substitute. Calvarial 
defects were filled with: (1) particles alone (n = 8), and (2) particles combined with PRP 
gel (n = 8), with a mixing ratio of 1 gram HA/β-TCP particles to 150 μl PRP. Some de-
fects were also left unfilled, which served as controls (n = 8). HA/β-TCP particles mixed 
with PRP were always applied directly after preparation.
PRP preparation
The whole blood of four male syngenetic Fisher 344 rats was drawn preoperatively 
via cardiac puncture into tubes containing 3.8% sodium citrate. Platelet-rich plasma 
(PRP) was obtained from this anticoagulated blood after centrifugation at 800 rpm for 
15 minutes at 25°C. The platelets present in the whole blood as well as present in 
PRP were counted automatically using a hematology analyzer (Advia 120, Bayer B.V., 
Mijdrecht, the Netherlands). The concentration of platelets obtained in the PRP was 3 
times higher than the baseline. The PRP was used as a PRP gel. Therefore, 150 μl of 
the platelet concentrate was activated at the time of surgery with 25 μl of 10% calcium 
chloride solution and 25 μl of 300 IU of bovine thrombin (300 IU) (FibriquikTM Throm-
bin, BioMerieux Inc., Durham, NC, USA).
Surgical procedure
Forty-five, 11 - 12 weeks old syngenetic male Fisher 344 rats, each weighing between 
220 and 260 g, were used in this study. National guidelines for the care and use of 
laboratory animals were observed.
Anesthesia was induced with 4% Isoflurane and maintained with 2% Isoflurane and 
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0.4% N2O, 0.4% O2 by non-rebreather mask and monitored to ensure that an appropri-
ate level of anesthesia was achieved and maintained for surgery. The animals were 
premedicated by an intramuscular injection of Fentanyl (3 ml/kg) (Hameln Pharmaceu-
ticals GMBH, Germany) to reduce the operative pain, and a subcutaneous injection of 
Buprenorphine (150 μg/kg) (Temgesic®, Reckitt Benckiser Healthcare Limited, UK) was 
applied to reduce the postoperative pain. Before surgery, the dorsal part of the rat cra-
nium was shaved and swabbed by iodine. A median sagittal incision extending from the 
nasofrontal area to the occipital protuberance was made and soft tissues were sharp 
dissected to visualize the cranial periosteum. The periosteum was then undermined 
and reflected, exposing the parietal bones. A hollow trephine bur with an outer diameter 
of 6.2 mm in a dental hand piece was used to create a full-thickness defect into the 
dorsal part of the parietal bone. Based on literature, we supposed that a 6.2 mm cranial 
defect would be a critical-sized defect in rats for one or two weeks of implantation. 
Bosch et al. (1998) and Verna et al. (2002) described 5 mm defects as critical-sized in 
testing materials for bone regeneration during implantation periods of 6 and 12 months. 
During the surgical procedure, the mid-sagittal suture was avoided in order to reduce 
the risk of damaging the superior sagittal sinus and to minimize the morbidity of the 
animals (Bosch et al. 1998; Verna et al. 2002). Care was also taken not to damage the 
dura mater or to puncture the superior sagittal sinus. Dense HA/β-TCP particles alone 
or in combination PRP gel were placed in a 6.2 mm cranial defect. Empty defects were 
used as control. For the implantation time of 1 week, seven defects were made in each 
group: empty defect (n = 7), HA/β-TCP alone (n = 7) and HA/β-TCP + PRP (n = 7). For 
the implantation time of 2 weeks, eight defects were made in each group: empty defect 
(n = 8), HA/β-TCP alone (n = 8) and HA/β-TCP + PRP (n = 8). After insertion of the vari-
ous materials, the periosteum and overlying skin were closed in separate layers with 
5 - 0 and 4 - 0 Vicryl resorbable sutures.
Histological preparation
The animals were euthanized 1 and 2 weeks after surgery using an overdose of carbon 
dioxide. The skin was dissected and the defect sites were removed along with sur-
rounding bone and soft tissues, and fixed in 10% neutral formalin for one week. First, 
specimens were used for μCT, thereafter specimens were used for histology. Part of 
the specimens used for histology (n  =  5 for the 1st week and n = 6 for the 2nd week) 
were decalcified for two weeks in Formical-2000 (Immunodiagnostika & Biotech GmbH, 
Berlin, Germany) and then embedded in Paraplast paraffin (Klinipath B.V., Duiven, the 
Netherlands). The two remaining specimens were left undecalcified (n = 2, both for 1st 
and 2nd week) and were embedded in polymethylmetaacrylate (PMMA). Before the 
embedding procedure, an incision was made exactly through the middle of the bone 
defects to secure that the microtome sections were made in the area of interest. Sagit-
tal paraffin sections, 5 μm in thickness, were stained with haematoxylin-eosin, and 
trichrome staining (Masson modification Goldner). Methylene blue and basic fuchsin 
were used as a staining for the PMMA samples, which were prepared using a modified 
diamond-blade sawing microtome technique and were 10 μm thick. Light microscopical 
analysis consisted of descriptive histology and was made using an optical microscope 
(Leica BV, Rijswijk, the Netherlands).
A scoring system was used to quantify defect closure. The scoring scale for the defect 
closure ranged from 0 to 4, where 0 represented a completely empty defect (0% clo-
sure), 1 corresponded to 25% defect closure, 2 to 50% defect closure, 3 to 75% defect 
closure and 4 to 100% defect closure.
μCT scan analysis
Before histological preparation, computerised X-ray microscopy and tomography of the 
samples (n = 6) was performed by μCT scanner with a very high spatial resolution (5 
μm corresponding to near 1 x 10-7 cubic mm voxel size) (Sky Scan 1072, Skyscan NV, 
Aartsellar, Belgium). For each sample, a total of 336 micro-tomographic slices were 
gained using a slice increment of 25 μm in order to scan the whole defect (6.2 mm) and 
the surrounding bone.
From the μCT scan datasets, 3D models were built for visualization and morphometric 
analysis. For the morphometric analysis, a subregion of the originally measured data 
was selected. This selected region of interest (ROI) included the whole defect area with 
the newly formed bone inside. By auto-interpolation of layers, ROI became volume of 
interest (VOI), which is the essential basis for all quantitative analysis. VOI was deter-
mined to be 15 mm3. It was calculated in advance using the formula V = π r2 h, where 
“r” is half of the diameter size of the original defect and “h” represents the thickness 
of the skull measured interactively or by a caliper. Images from only the axial projec-
tion of the skull were taken, which resulted in 207 layers covering the whole defect. It 
turned out that VOI of 15 mm3 with a pixel size of 21.88 μm corresponded to 207 layers. 
Within the VOI, the volume of the particles and the volume of the newly formed bone 
were calculated as a percentage or as volume of the newly formed bone, and particles, 
respectively.
It was possible to identify accurately the newly formed bone from the HA/β-TCP par-
ticles when the raw data reconstructed cross-sections were turned into images. Each 
image used 256 gray scales. Based on histogram calculations, the bone was defined to 
be in the 64 - 225 gray value range, whereas the particles were regarded to lie between 
0 and 63.
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Statistical analysis
For the statistical analysis GraphPad InStat® (GraphPad Software, Inc.) was used. One-
way Analysis of Variance (ANOVA) was performed on the raw data obtained from μCT 
analyses. ANOVA assumes that the data are sampled from populations with identical 
standard deviations. This assumption was tested using the method of Bartlett. Further, 
ANOVA assumes that the data are sampled from populations that follow Gaussian 
distributions. This assumption was tested using the method Kolmogorov and Smirnov. 
In addition, Tukey-Kramer Multiple Comparisons Test was done.
Results
All animals had an uneventful recovery. Their weight remained stable and increased 
during the implantation period, whereas no infection occurred during that time.
Descriptive histology
One week results
Light microscopic examination of the decalcified sections showed that bone formation 
had already started in the 1st week for all experimental groups. Newly formed bone 
could be observed at the defect borders and at the side of the dura (Figure 1). 
Figure :  Start of bone formation during the st week mainly at the side of the dura. Undecalcified samples embed-
ded in PMMA and stained with Methylene Blue-Basic Fuchsin, 2.5 x magnification. 
A) empty defect, B) defect with particles,  C) defect with particles and PRP.
* newly formed bone; # old skull bone; p particles.
Its morphology was the same in all groups, i.e. a woven structure without preferred ori-
entation of the collagen fibers in the bone matrix and an abundance of osteoblasts and 
small blood vessels. No signs of bone remodeling or presence of osteoclast-like cells 
were seen neither were signs of inflammation present. 
The defect closure was estimated subjectively to be between 10 and 50% in all samples, 
whereas no difference among the groups appeared to occur. Only in groups with im-
plants, the HA/β-TCP particles were surrounded by a fibrous tissue layer while embedded 
in bone matrix. It has to be emphasized that no effect of the use of PRP on bone formation 
was seen.
Trichrome staining revealed the start of neovascularisation during the 1st week, whereas 
no difference in the number of blood vessels between the PRP and non-PRP groups was 
detected subjectively.
The histological findings of the undecalcified methylene blue/basic fuchsin stained sam-
ples were completely similar to the decalcified hematoxylin-eosin stained slides and did 
not provide additional information. 
Two weeks results
After two weeks, complete bridging of the bone defect was observed for most of the empty 
defects, as well as for the defects that contained only HA/β-TCP particles. The HA/β-TCP 
filled defects seemed to support more bone formation in comparison to the PRP/HA/β-
TCP filled defects. On the other hand, the layer of newly formed bone in the empty defects 
was thinner than the layer of newly formed bone in both particle groups (Figure 2).
Figure : Bone formation after  weeks. The layer of newly formed bone in the empty defects is thinner than 
the layer of newly formed bone in both particle groups. Decalcified paraffin samples stained with hematoxylin-
eosin (H.E.), 2.5 x magnification. A) empty defect, B) defect with particles, C) defect with particles and PRP. 
* newly formed bone; # old bone; p particles.
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Examination of the PRP and non-PRP samples revealed that in both groups some of 
the HA/β-TCP particles were almost completely surrounded by bone without an inter-
vening fibrous tissue layer. Evidently, newly formed bone was guided over the outer 
surfaces of the particles (Figure 3). 
Figure 3: Particles directly embedded in bone without fibrous tissue interface after 2 weeks. A) Paraffin sample 
(10 x magnification, H.E.), B) PMMA sample  (10 x magnification, Methylene Blue-Basic Fuchsin).
* newly formed bone; ← lack of fibrous tissue interface; p particles.
The trichrome staining showed in general more mature bone (stained in red) in the 
second week compared to the first week (stained in green) (Figure 4). 
Figure : More mature bone (stained in red) at the nd week compared to the st week. Decalcified paraffin samples 
with Trichrome staining (Masson modification Goldner), 2.5 x magnification. A) 1st week, B) nd week.
* newly formed bone;  #  old bone; p particles.
No difference in vascularisation was observed subjectively in the number of the blood 
vessels among all groups. However, neovascularisation was more evident after 2 
weeks. 
The histological findings of the non-decalcified samples were again comparable with 
the decalcified sections.
μCT analysis
Bone formation in the skull defects (n = 6, randomly selected) was also imaged with μCT. 
μCT images confirmed the uniform distribution of the particles throughout the defects for 
both PRP and non-PRP groups. Only occasionally, some particles were observed outside 
the defect.
Although the tomographic X-ray images suggested that no bone formation had occurred 
neither in the empty nor in the grafted defects, the 3D reconstructed representations dem-
onstrated a completely different result. In these reconstructions, bone formation could 
already be detected after the 1st week of implantation in all experimental groups. The 3D 
models of the filled defects showed penetration of the newly formed bone between the 
particles already after one week. At the second week, the bone ingrowth from the side of 
the dura and the defect borders was especially prominent. Also, in the empty defects start 
of new bone formation was observed after one week, whereas some of the defects were 
almost completely closed after 2 weeks (Figure 5B, C). 
Figure 5: μCT images A) radiograph of a defect with particles at the 2nd week: particles uniformly distributed throughout 
the defect, bone ingrowth cannot be recognized, B) D model of an empty defect at the st week: start of new bone 
formation from the side of the dura and from the defect edges, C) D model of an empty defect at the nd week: almost 
complete defect closure.
The data from the morphometric analysis are presented in Figure 6 and show that the 
amount of newly formed bone after 1 week in the ROI, expressed as relative volume, 
ranged from 3.57% (empty defects) to 14.86 % (HA/β-TCP group). This difference was 
statistically significant (p < 0.01). On the other hand, no significant difference existed 
between the PRP and non-PRP HA/β-TCP particulate groups.
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At the second week, the volume of the newly formed bone was increased to 14.5% for the 
empty defects, 19.9% for the HA/β-TCP and 17.2% for the HA/β-TCP + PRP. Statistical 
analysis revealed that these differences were not statistically significant (p = 0.1745). 
A comparison of the results from both implantation times showed that there was a sig-
nificant difference in the bone formation rate for the group with empty defects between 
the 1st and 2nd week. However, no statistically significant difference in the amount of the 
newly formed bone was observed between both particulate groups at 1 and 2 weeks of 
implantation.
Discussion
Platelets and platelet-derived growth factors are known to be effective during the early 
stage of bone graft healing, because the life span of a platelet in a wound and the 
period of direct influence of its GFs are less than 5 days (Choi et al. 2003). Therefore, 
a pronounced effect of PRP is supposed to occur especially during the early stages of 
bone regeneration. However, in our study, after 1 and 2 weeks of implantation of HA/
β-TCP particles mixed with PRP in rat skull defects, no significant difference in bone 
formation between the PRP and non-PRP groups was observed, neither histologically 
nor by μCT evaluation. Evidently, no positive effect of PRP on bone formation could be 
confirmed. This corroborates the study of Butterfield et al. (2005), who performed max-
illary sinus augmentation in rabbits with autogenous bone graft and PRP. After 2, 4 and 
8 weeks of implantation Butterfield et al. also failed to prove a direct stimulatory effect of 
PRP on bone healing. On the other hand, they found a statistically significant difference 
in total bone area and bone formation rate between 2 and 4 weeks in the PRP group. 
This founding is in contrast to the hypothesis that most of the effect of PRP will occur 
during the very early healing period. These results agree also with the summary of the 
μCT analysis from our previous (Plachokova et al. 2006) and current study. 
On the other hand, our findings contradict those of Schlegel et al. (2004), who re-
ported a significant accelerating effect of PRP on early bone regeneration (2 weeks) 
in combination with autogenous bone applied in the forehead area of pigs. At the 2nd 
week, they showed microradiographically a maximum rate of 63% mineralization in 
the PRP groups and this peak level occurred 2 weeks earlier than in the group using 
autogenous bone alone. In addition, more new blood vessels were observed histologi-
cally when PRP was applied. Several explanations can be given for this discrepancy in 
observations. Firstly, the technique to prepare PRP and the concentration of the gained 
thrombocytes can differ. Schlegel et al. (2004) managed to achieve a 4.1- and 6.5- fold 
increase of pig platelets above the baseline. The rat PRP that we produced had 3-
fold increase. Nevertheless, despite the smaller number of platelets in the rat PRP, a 
substantial number of GFs have been proven to be present there (unpublished data). 
Secondly, differences between the used animals (age, breed) can play a role. Thirdly, 
better results with PRP are reported when it is combined with autogenous grafts and 
not with allogenic materials (Wiltfang et al. 2004). 
Considering the results of the orthotopic application of dense HA/β-TCP particles, our 
current findings are in keeping with our previous study (Plachokova et al. 2006). It 
was confirmed again that dense HA/β-TCP (60%/40%) particles with a size of 300-500 
µm are indeed osteoconductive, as the new bone formation was guided by the outer 
surfaces of the particles and resulted in larger amount of newly formed bone in com-
parison to the empty defects. After 2 weeks some of the particles were also completely 
embedded in bone without an intervening fibrous tissue. Evidently, dense HA/β-TCP 
particles did not cause any inflammatory reaction. It was also evident again that a 6 
mm cranial defect in Fisher rats is not a critical-sized defect (CSD), since at two weeks 
most of the empty defects were already closed with bone tissue. Although, some other 
reports claim that defects with a diameter of 4 - 5 mm have to be considered as CSDs 
(Mulliken & Glowacki 1980; Bosch et al. 1998), our data demonstrated that a full thick-
ness defect with a diameter of 6.2 mm in rat calvaria shows a tendency for almost 
complete closure within 2 weeks (Figure 5C). An explanation for this inconsistency in 
defect closure versus defect diameter could be the evaluation technique as used in 
various studies. For example, Duporieux et al. (1999, 2001) created also 6 mm sized 
calvarial defects in Wistar rats with the same weight as in our study (between 250 and 
300 g). They suggest that empty control defects are still open after healing periods of 
6 - 9 weeks. However, their conclusion is based on a radiographic analysis. In the cur-
rent study, but also in an earlier publication (Hedberg et al. 2005), we observed that an 
incongruity exists between the 2D X-ray image and a 3D μCT reconstruction. New bone 
formation was observed after the 1st week in a 3D model, while it was not possible to 
detect bone formation on the tomograms. In view of this, it has to be emphasized that 
only 3D models based on computerized tomograms, as made of the complete defect 
site, can visualize the final spatial distribution of the newly formed bone and the direc-
tion of the bone formation over the total defect area.  
Finally, in our present study the options of different μCT software programs for mor-
phometric analysis were explored more profoundly. Basically, the same approach was 
applied as in our previous study (Plachokova et al. 2006). The difference was that this 
time images were taken only from the axial projection of the skull and not from the 
transversal, which resulted in 207 layers covering the whole defect. It appeared that the 
same VOI of 15 mm3 with pixel size of 21.88 μm corresponded to 207 layers. Apart from 
the larger number of slices that we obtained, 207 in comparison to 20, it was easier to 
follow the ROI in an axial aspect. Another advantage of this approach was that ROI was 
drawn by hand (i.e. the polygonal freehand drawn ROI) independently for each layer, 
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which enabled a more precise position of the borders of the ROI. Despite the intro-
duced changes, the results that we obtained from the current morphometrical analysis 
were consistent with the results from our previous study. All the data were put together 
in Figure 6 to follow the trend of bone regeneration, which appeared to be linear. All 
this implies that irrespective of the used algorithm, currently the μCT analysis remains 
a very reliable source of information in the field of bone research. 
Conclusion
Based on our results, we conclude that a 6.2 mm cranial defect is not a critical-sized 
defect in rats. Further, to our knowledge this is one of the few studies that investigated 
the early effect of PRP on bone regeneration. However, no effect at all of rat PRP on 
healing of cranial bone defects in combination with synthetic bone substitute was ob-
served. Further, dense HA/β-TCP (ratio 60%/40%) particles with a size of 300-500 μm 
were found to have a beneficial effect on bone formation already after 1 and 2 weeks of 
implantation in rat cranial defects. 
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Introduction
In an attempt to create a bone graft, which is comparable or superior to bone, al-
lografts are combined with osteoinductive substances, such as growth factors (GFs). 
Several recombinant GFs have been produced and numerous studies have shown 
their beneficial impact on bone healing. Besides the demonstrated positive effects of 
human recombinant GFs in bone regeneration, there are also some disadvantages to 
be overcome, such as short shelf-life, inefficient delivery to target cells, high price, and 
dose-dependent effect. 
Platelet-Rich Plasma (PRP), as a rich source of autologous growth factors, can be 
regarded as an alternative approach. It was first introduced in 1998 by Marx et al. in 
combination with autogenous bone grafts for reconstruction of mandibular continuity 
defects. Their study showed that addition of PRP to bone grafts resulted both in a 
faster radiographic maturation rate (1.62 to 2.16 times) and higher bone density than 
the control group (Marx et al. 1998). Since then, the effect of PRP on bone regeneration 
has been extensively investigated, while also different techniques to prepare PRP have 
been developed. Clinical studies and case reports on sinus floor elevation, alveolar 
ridge augmentation, mandibular reconstruction, maxillary cleft repair and periodontal 
regenerative procedures have already described the beneficial effect of PRP in addition 
to autogenous bone, anorganic bone mineral, organic bone substitutes or when used 
alone (Whitman et al. 1997; Obbario et al. 2000; Kassolis et al. 2000; Camargo et al. 
2002; Fennis et al. 2002, 2004; Lekovic et al. 2003; Rodriguez et al. 2003; Wiltfang et 
al. 2003). Mitogenic effects of PRP on osteoblast-like cells were seen in vitro (Weibrich 
et al. 2002). On the other hand, some experiments showed only a limited or no benefi-
cial effect of PRP on bone formation. Schmitz & Hollinger (2001) even expressed their 
concern about the insufficient biological understanding of the clinical therapy surround-
ing PRP. They pointed out that the exact effects of PRP on bone formation are still 
unknown and suggested further research.
The basic hypothesis of the addition of PRP to bone grafts is that a high concentration 
of platelets in a bony wound will increase the local concentration of secreted GFs and 
subsequently enhance initial bone regeneration. After a few days, the direct influence 
of the administered PRP will fade away and physiological mechanisms of bone repair 
continue to work on an accelerated level (Jakse et al. 2003). The following GFs are 
reported to be present in PRP: Platelet Derived Growth Factor in its three isoforms 
(PDGFαα, ßß, αß), Transforming Growth Factors-beta (TGF-ß1 and TGF-ß2), Vas-
cular Endothelial Growth Factor (VEGF) and Epithelial Growth Factor (EGF), as well 
as three blood proteins known to act as cell adhesion molecules for osteoconduction: 
fibrin, fibronectin and vitronectin (Marx et al. 1998; Marx 2004). According to some au-
thors PRP is also a storage vehicle for basic Fibroblast Growth Factor (bFGF), Insulin 
Growth Factor-1 (IGF-1), Platelet Factor-4 (PF-4), and interleukine-1 (Aghaloo et al. 
2002; Tozum & Demiralp 2003; Sanchez et al. 2003). All this implies that PRP might 
influence bone formation through a variety of pathways.
In our study, we hypothesized that PRP might possess osteoinductive properties and 
thus applied in addition to HA/ß-TCP as a scaffold material may enhance bone forma-
tion. It was decided to compare the effect of PRP in form of a liquid and PRP in form of a 
gel, to see if the addition of the clot formation accelerators, thrombin and calcium chlo-
ride, influences the bone formation and adds to the initial stability of the implant. This 
is one of the first studies that investigates whether there is a difference in the activity 
of PRP either in a gel or a liquid form, while combined with biphasic ceramic particles. 
Besides histology, specimens were evaluated using high resolution X-ray computed 
tomography (μCT). Decision was taken to combine PRP with biphasic ceramic particles 
composed of 40% beta-tricalcium phosphate (ß-TCP) and 60% hydroxyapatite (HA) 
(Camceram, CAM Implants, Leiden, the Netherlands), because this material is well 
studied and is already in clinical use as a bone graft substitute. HA/ß-TCP is osteocon-
ductive and slowly degradable. 
 
Materials and Methods
Bone fillers
Dense HA/ß-TCP (60%/40%) particles were used as synthetic bone substitute with 
a size of 300-500 μm (Camceram CAM Implants, Leiden, the Netherlands). For the 
animal group, where the defects were filled with particles alone, 1 gram of the particles 
was mixed immediately before implantation with 100 μl blood. When particles were 
inserted together with PRP liquid, the mixing ratio was 1 gram HA/ß-TCP particles to 
150 μl PRP. The same ratio was used when HA/ß-TCP particles were combined with 
PRP gel. All the mixtures were prepared in the immediate preoperative time and ap-
plied right away.
PRP preparation
The whole blood of four male Fisher 344 rats was drawn preoperatively via cardiac 
puncture into tubes containing 3.8% sodium citrate. PRP was obtained from this anti-
coagulated blood after centrifugation at 800 rpm for 15 minutes at 25° C. Three ml of 
blood resulted in 150 μl of PRP. The platelets present in the whole blood and present in 
PRP were counted automatically using a hematology analyzer (Advia 120, Bayer BV, 
Mijdrecht, the Netherlands). The concentration of platelets achieved in the PRP was 3 
times higher than the baseline. The PRP was used as prepared or to obtain PRP gel. 
Chapter  The Late Bone Regenerative Effect of PRP
4 4
 
Therefore, the platelet concentrate was activated at the time of surgery with a 10 % cal-
cium chloride solution and 300 IU of bovine thrombin. One hundred and fifty micro liters 
of PRP was mixed with 25 μl Thrombin (300 IU) (FibriquikTM Thrombin, BioMerieux 
Inc., Durham, NC, USA) together with 25 μl 10% CaCl2.
Surgical procedure
Thirty-eight syngenetic male Fisher 344 rats, each weighing between 220 and 260 g, 
were used in this study. National guidelines for the care and use of laboratory animals 
were observed.
Dense HA/ß-TCP particles alone or in combination with PRP liquid or PRP gel (n = 10) 
were placed in a 6.2 mm cranial defect. Eight defects (n = 8) were left empty as control. 
In this way, four groups were created, i.e. empty defects, defects with HA/ß-TCP parti-
cles, HA/ß-TCP particles combined with PRP and HA/ß-TCP combined with PRP gel.
Anesthesia was induced with 4% Isoflurane and maintained with 2% Isoflurane and 
0.4% N2O, 0.4% O2 by non-rebreather mask and monitored to ensure that an appropri-
ate level of anesthesia was achieved and maintained for surgery. To reduce the post-
operative pain the animals were premedicated by an intramuscular injection of Fentanyl 
(3 ml/kg) and subcutaneous injection of Buprenorphine (150 μg/kg). Before surgery, the 
dorsal part of the rat cranium was shaved and swabbed by iodine. A median sagittal in-
cision extending from the nasofrontal area to the occipital protuberance was made and 
soft tissues were sharp dissected to visualize the cranial periosteum. The periosteum 
was then undermined and reflected, exposing the parietal bones. A hollow trephine bur 
with an outer diameter of 6.2 mm in a dental hand piece was used to create a full-thick-
ness defect (Bosch et al. 1998) into the dorsal part of the parietal bone (Fig.1). 
Figure : Surgical procedure: the . mm full- thickness defect is placed aside from the sagittal suture- a defect with 
particles
During the surgical procedure, the mid-sagittal suture was avoided in order to reduce 
the risk of damaging the superior sagittal sinus and to minimize the morbidity of the 
animals (Bosch et al. 1998; Verna et al. 2002). Care was also taken not to damage 
the dura mater or to puncture the superior sagittal sinus. After insertion of the various 
materials, the periosteum and overlying skin were closed in separate layers with 4-0 
Vicryl resorbable sutures.
Histological preparation
The animals were euthanized 4 weeks after surgery using an overdose of carbon diox-
ide. The skin was dissected and the defect sites were removed along with surrounding 
bone and soft tissues, and fixed in 10% neutral formalin for one week. After that, the 
specimens were decalcified in Formical-2000 (Immunodiagnostika & Biotech GmbH, 
Berlin, Germany) for one week and then embedded in Paraplast paraffin (Klinipath 
B.V., Duiven, the Netherlands). Before the embedding procedure, an incision was made 
exactly through the middle of the bone defects to secure that the microtome sections 
were made in the area of interest. 
Sagittal sections of about 5 μm in thickness were prepared, stained with haematoxylin-
eosin and observed under an optical microscope (Leica BV, Rijswijk, the Netherlands). 
Light microscopical analysis consisted of descriptive histology and histomorphometri-
cal analysis.
Histomorphometry
For histomorphometry a scoring system was used to quantify defect closure and bone 
bridging at the defect border. The scoring scale for the defect closure ranged from 0 
to 4, where 0 represented a completely empty defect (0% closure), 1 corresponded to 
25% defect closure, 2 to 50% defect closure, 3 to 75% defect closure and 4 to 100% 
defect closure.
Bridging at the defect border was defined as the occurrence of bone formation between 
the defect border and the HA/ß-TCP particles in the defect. The grading scale for the 
bridging at the defect border ranged from 0 to 2, where 0 stands for no bridging, 1 for 
bridging at one defect border and 2 for bridging at two defect borders.
Further, image analysis was performed on three digitalized sections per specimen to 
quantify the bone area within the defect, which is considered to be the newly formed 
bone. For this purpose, a Leica® Qwin Pro-image analysis system (Leica BV, Rijswijk, 
the Netherlands) was used and sections were digitized at low magnification. The newly 
formed bone, as defined by its woven structure and location, was marked in an inter-
active manner, and the computer calculated its surface area (BA) in mm2 (Fig. 2a). 
Another parameter to determine was the region of interest (ROI) in mm2, defined as 
the surface of the area between the defects borders that had to be filled with the newly 
formed bone (Fig. 2b). For the calculation of ROI, the thickness of the skulls was taken 
into account, as they were measured in advance using a caliper. From these two data, 
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the bone fill percentage (%) i.e. the index of the bone surface area (BA) divided by ROI 
was calculated. Presented results are based on the average of these measurements.
Figure :  Histomorphometric measurements:
A) newly formed bone marked in an interactive manner and defined as bone surface area (BA)
B) region of interest (ROI) marked in an interactive manner
X-ray imaging and μCT scan analysis
Directly after retrieval of the samples X-ray imaging was performed by a μCT scanner 
(Sky Scan 1072, Skyscan NV, Aartselaar, Belgium). Due to the rotation of the objects, 
radiographs in different positions were taken of each sample. In this way the appropri-
ate area or position for the three-dimensional (3D) reconstruction could be selected 
and further the X-ray images could be compared with the 3D images.
New bone formation within the defects (n = 4) was evaluated using the same μCT scan-
ner. Specimens were fitted in the middle of a cylindrical sample holder with the coronal 
aspect of the calvarial bone in a vertical position. High-resolution scanning and cone 
beam reconstruction were performed with a pixel size of 25.76 μm and slice thickness 
of 25 μm. The number of slices was set at 20, to cover the entire thickness of the cal-
varial bone. This was according to the preliminary determined thickness of the skull (20 
layers = 0.5 mm), as measured with a caliper and the interactive measurements of the 
cross-section of the sample. The μCT software was used to make a 3D reconstruction 
from the obtained set of scans.
Out of the entire 3D data set, a cylindrical ROI with a diameter of 6.18 mm and a height 
that covered the entire thickness of the calvarial bone was selected for analysis. Its 
volume, VOI = 15 mm3, was calculated in advance using the formula V = π r2 h, where 
“r” is half of the diameter size of the original defect and “h” represents the thickness of 
the skull measured interactively or by a caliper. This volume corresponds to 20 layers. 
ROI was placed where the original defect was located since the margins of the original 
defect were visually recognizable. Within the ROI, the volume of the particles and the 
volume of the newly formed bone were calculated as a percentage.
The computer program calculated the gray values and the number of voxels with the 
corresponding gray values in the ROI. A histogram was used to establish which range 
of gray values should be regarded as bone and which as HA/ß-TCP particles. The 
gray values of the particles and the bone were defined for each sample independently. 
Applying the threshold according to the histogram, care was taken to eliminate the at-
tenuation of the particles as much as possible since they were visually recognizable. In 
summary, bone was defined to be in the 129-246 gray value range, whereas the HA/
ß-TCP particles were regarded to lie in the 0-128 gray value range.
The amount of newly formed bone in the ROI was expressed as relative volume. It 
was calculated in a percentage as the amount of voxels with bone-related gray values 
divided by the total number of voxels.
Statistical analysis
One-way Analysis of Variance (ANOVA) was performed on the raw data obtained from 
μCT and histomorphometry analyses. ANOVA assumes that the data are sampled from 
populations with identical standard deviations. This assumption was tested using the 
method of Bartlett. Further, ANOVA assumes that the data are sampled from popula-
tions that follow Gaussian distributions. This assumption was tested using the Kol-
mogorov and Smirnov method.
Results
All animals had an uneventful recovery. Their weight remained stable and increased 
during the implantation period. Further, no infection occurred during that time.
Descriptive histology
Light-microscopic examination of the sections showed new bone formation and almost 
complete defect closure in all groups after four weeks. Newly formed bone layer was 
thinner than the surrounding skull bone. The defect borders were still visible. Newly 
formed bone was characterized by the presence of osteoblasts, osteocytes and an 
abundance of small blood vessels. The bone had a woven structure without preferred 
orientation of the collagen fibers in the bone matrix. No signs of bone remodeling or 
presence of osteoclast-like cells were seen, neither were signs of inflammation ob-
served.
Despite the decalcification procedure, the HA/ß-TCP particles could be easily recognized 
in the skull defects because a circular space was left for the area that was previously 
occupied by the particles. Analysis revealed that frequently the HA/ß-TCP particles were 
found to be encapsulated by a thin fibrous tissue layer, while embedded in a bone matrix. 
Occasionally, particles were also surrounded directly by bone (Fig. 3). At the defect bor-
ders, bone had bridged the gap between the defect border and the inserted HA/ß-TCP 
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particles. 
Overall, no differences in morphology or appearance of newly formed bone were ob-
served among the various groups.
Figure 3: HA/TCP- b particles surrounded by thin fibrous tissue layer and embedded in bone, H& E staining 
A) 20x magnification  B) 40x magnification
Histomorphometry
Histological scoring confirmed the subjective evaluation. We observed that two defects 
of the empty defect group, three of the particle group, two of the particles + PRP group 
and two of the particle + PRP gel group were completely closed. On average the defect 
closure was about 75% for all groups (Fig. 4). Statistical testing showed that no signifi-
cant differences existed among the groups (p > 0.05). Figure 4 also shows the data of 
the scoring for bone bridging at the defect borders. 
Figure : Defect closure and bridging at the defect border
Some examples for bridging at the defect borders are presented at Figure 5. Statistical 
testing again did not reveal the presence of significant differences among the various 
defect groups. 
Figure 5: Bridging at the defect border, 2.5x magnification, H&E staining
A) score 0-no bridging      B) score -bridging at one defect border       C) score -bridging at two defect borders
Results of the measurements of bone fill percentage in the various defects are pre-
sented in Figure 6. The amount of bone formation ranged from 61 % to 75 %. Statisti-
cal testing could not reveal any difference in bone fill percentage between the various 
groups.
Figure : Histomorphometric and micro-CT measurements of the amount of the newly formed 
bone within the defect
X-ray imaging and μCT analysis
Bone formation in the skull defects was also imaged with μCT. In the empty defect 
new bone formation could be observed clearly on radiographs as well as on 3D mo-
dels. However, the original drill defect was still visible. In the particle-filled defects, the 
particles were observed uniformly distributed through the defect (Fig. 7). The particles 
were maintained very well in the skull defect. Only occasionally, some particles were 
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observed outside the defect. On the 3D images bone formation was especially promi-
nent at the bottom of the particles. Bone had also penetrated in between the particles 
and resulted in almost complete 3D closure of the defect. Figure 6 shows the quantita-
tive data for the bone volume percentage in the various defects. As it can be seen, the 
amount of newly formed bone in the ROI expressed as relative volume ranged from 
34 % (empty defects) to 39 % (HA/ß-TCP + PRP group). No significant differences 
were observed among the groups.
Figure : Micro-CT images
A) Radiograph of a defect with HA/TCP particles B) D reconstruction of the same sample
C) D reconstruction of the particles alone in the same sample
Discussion
The aim of this study was to investigate the effect of PRP on bone regeneration in 
combination with an osteoconductive material. Fisher 344 rats were animals of choice 
in this experiment, because they are syngenetic. Therefore, the requirement of PRP as 
an autologous product is fulfilled and the risk of having false-negative results because 
of an immune reaction is minimized (Marx 2004). We also managed to achieve in the 
prepared PRP a 3-fold increase of platelets above the baseline, which is in correspon-
dence with the concentration of platelets obtained by one of the FDA approved devices 
(3i PCCS, 3i Implant Innovations, West Palm Beach, FL, USA) (Marx 2004). 
From the literature (Schmitz & Hollinger 1986), it is known that in rat calvaria the critical-
sized defect is 8 mm in diameter after 12 weeks of implantation. On the other hand, 5 
mm defects were also described as critical-sized in testing bone-regeneration materials 
(Bosch et al. 1998; Verna et al. 2002). Based on the literature, we supposed that a 6.2 
mm cranial defect would be a critical-sized defect for a 4 weeks implantation period in 
rats. However, the cranial defects that were prepared, despite being 6.2 mm in diam-
eter and grafted for such short implantation period, turned out to be non critical-sized. 
An explanation for this discrepancy in results can be the age of the used rats. In our 
study, the rats were young (11-12 weeks). The capacity of immature animals for ac-
celerated regeneration is well known. Besides age, also species may play a role in the 
rate of the healing process. 
After four weeks of implantation, no significant difference in bone formation between 
all groups was observed, neither histologically nor by μCT. No positive effect on bone 
formation of PRP could be determined. This is in agreement with various other studies 
that evaluated the use of PRP in combination with synthetic bone substitute materials 
(Froum et al. 2002; Fuerst et al. 2003; Wiltfang et al.2004). For example, Wiltfang et al. 
(2004) showed no additional benefit when PRP was applied with xenogenic bone sub-
stitutes, such as TCP granules (Cerasorb®), bovine spongious blocks (BioOss®) and 
collagenous sponge (Colloss®), in critical-sized defects in mini pigs for the same im-
plantation period of four weeks. In a human study with sinus floor lift grafts, Froum et al. 
(2002) found histologically no benefit by the addition of PRP to BioOss®. On the other 
hand, Kim et al. (2001) grafted rabbit cranial defects with BioOss® with or without PRP, 
and reported increased bone density in computed tomography scans at one month 
when PRP was used. Aghaloo et al. (2004), also in the rabbit cranial model, showed 
histomorphometrically that the addition of PRP significantly increased the percentage 
of bone formation over that of BioOss® alone for the same time period (4 weeks). 
The fact that in this study PRP did not appear to have any beneficial effect on bone 
regeneration may be due to the selected implantation time and/or the non critical-size 
of the created skull defects. Platelets and platelet-derived growth factors are known to 
be effective during the early stage of bone graft healing, as the life span of a platelet 
in a wound and the period of the direct influence of its GFs is less than 5 days (Choi et 
al. 2003). A pronounced effect of PRP will, therefore, especially occur during the early 
stages of bone regeneration. The defects were also non-critical sized with a tendency 
to spontaneous healing already within four weeks of implantation. This might have 
prevented PRP to exert its presumed positive influence. The used PRP preparation 
technique may even influence the final study outcome. The preparation of PRP from a 
limited amount of rat blood is not a standard procedure. We followed a protocol used 
in rat experiments in cardiovascular medicine, where PRP is frequently applied (Yang 
& Fareed 1997). One of the reasons for choosing this particular protocol was the low 
centrifugal speed. It is known that the centrifugal speed can influence platelet activation 
and trigger platelet secretory processes in the plasma during the preparation of platelet 
concentrates (Kim et al. 2001). By applying a lower centrifugal speed, we supposed to 
have reduced the chance of occurrence of this phenomenon. The protocol was further 
adjusted to our needs in order to obtain a platelet concentration, which is considered to 
be sufficient for inducing a positive effect on bone regeneration (Marx 2004). Weibrich 
et al. (2004), who have extensively studied and compared different devices for produc-
ing PRP, demonstrated in an in vivo experiment that PRP has a very limited range of 
platelet concentrations to exert a positive impact on bone regeneration. Their study 
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showed that at lower concentration the effect is suboptimal, while higher concentrations 
might have an inhibitory effect. Therefore, we suppose that with the protocol used for 
the production of PRP, this intermediate therapeutic level of platelet concentration and 
hence, growth factor release was achieved. 
The results showed no difference between the effects of PRP liquid or gel on bone for-
mation. Apparently, the only function of thrombin and calcium chloride is to initiate the 
coagulation process. Still, we have to emphasize that PRP gel increased the handling 
capacity of the graft because it made the HA/ß-TCP particles stick together. However, 
the whole blood in combination with the HA/ß-TCP particles also enabled easier han-
dling of the graft, as it made the particles to stay in place.
Considering the biphasic ceramic (60% HA and 40% ß-TCP) that was used, it proved 
to be osteoconductive. Although the particles did not have an additional favorable ef-
fect, they also did not hamper bone formation. This confirms the osteogenic nature of 
this material and warrants further investigation to the clinical efficacy in critical-sized 
defects. 
As to the methods of evaluation, μCT scanning revealed its great potential in the field of 
bone research. Although it cannot replace the conventional histology, it promises to be 
one of the most reliable tools for the estimation of bone ingrowth. It has several advan-
tages, such as it is a non-invasive method, specimens do not need special preparation 
in staining, embedding and cutting, and it is less time consuming. μCT also provides 
us with a larger number of slices than are usually used for histomorphometry (in our 
study 3 versus 20). That explains the higher precision of results and the higher chance 
on statistically significance compared with histomorphometry (Bernhardt et al. 2004). 
The calculated volume fraction of bone is based on the true spatial distribution of the 
material as opposed to extrapolating a volume-based (3D) quantity from a limited set 
of surface-based (2D) measurements (Verna et al. 2002). In this study, the discrepancy 
between the histological sections and the 3D images became very obvious. It turned 
out that the real bone formation could be evaluated only in the 3D model as it presented 
the complete spatial distribution of the newly formed bone. The 3D image also made it 
possible to follow the direction of the bone formation over the total defect area, which is 
especially relevant when particles were applied. In this way we can distinguish whether 
the particles are lying on the top of the defect or are embedded in bone. All this con-
firms that 3D images are the most reliable source of information, although there are still 
problems to be solved with this technique. Some of the difficulties that we encountered 
were related to the method of calibration and the elimination of the attenuation of the 
particles. We relied mainly on the histogram defined for each sample independently 
in order to determine the gray value range of the particles and the bone. This might 
be regarded as a subjective calibration, rather than an objective one, which is usually 
performed by means of a phantom model. 
In summary, our experiment revealed that PRP had no effect on bone formation for 
the selected implantation time, independent whether it was applied in the form of a 
liquid or gel. There was also no difference between PRP liquid and PRP gel, except 
for the beneficial effect of the gel on the ease of handling of the graft. Dense HA/ß-
TCP (60%/40%) particles, with a size of 300 - 500 μm proved to be osteoconductive. 
Further investigations are necessary to elucidate the influence of PRP on osseous 
regeneration, especially in the early stages of bone healing.
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Introduction
The effect of platelet-rich plasma (PRP) on bone regeneration has been studied exten-
sively since it was first introduced in 1998 by Marx for maxillo-facial reconstructions [1]. 
Defined as an “autologous concentration of platelets in a small volume of plasma”[2], 
PRP is considered to be a rich source of growth factors (GFs) as present in the alpha- 
(α-) granules of blood platelets, i.e. Platelet Derived Growth Factor (PDGF) in its three 
isoforms (αα, ββ, αβ), Transforming Growth Factor (TGF) in its two isoforms (TGF-β1 
and TGF-β2), Vascular Endothelial Growth Factor (VEGF), Epithelial Growth Factor 
(EGF), Insulin-like Growth Factor 1 (IGF-1) and basic Fibroblast Growth Factor (bFGF), 
as well as three blood proteins known to act as cell adhesion molecules (fibrin, fibro-
nectin and vitronectin) [1-4]. GFs released upon the activation of platelets are supposed 
to bind to the transmembrane receptors of osteoprogenitor cells, endothelial cells, and 
mesenchymal stem cells, and subsequently influence the bone regeneration process 
through a variety of pathways. The basic hypothesis of the addition of PRP to bone 
grafts is that high concentrations of platelets in a bony wound will increase initially the 
local concentration of GFs and subsequently enhance the early bone healing response. 
In a later stage, the direct influence of PRP will decrease and physiological mechanisms 
of bone repair will continue to work at an accelerated level [5]. In addition to the present 
GFs, PRP can influence the bone healing due to its cohesive and adhesive nature. Used 
in the form of a gel, PRP improves the handling capacity of a graft material with which it 
is combined, by facilitating graft placement and stability. These features of PRP enable 
better space maintenance and accelerated bone regeneration. 
Although all the above mentioned suggests a huge potential of PRP for the treatment 
of bone defects, experimental as well as clinical trials are not consistent regarding 
the impact of PRP on bone healing [6-14]. Moreover, systematic reviews on the topic 
of PRP can not yet provide solid evidence for the efficacy of PRP application in bone 
regeneration and augmentation procedures [15,16]. In fact, currently, a lot of confu-
sion exists around the efficacy of PRP treatment in various studies. The contradictory 
reported PRP treatment outcomes can be due to several reasons, including differences 
in experimental (animal, human) and bone defect models (critical-, non-critical-sized 
defects), differences in PRP biology among species, differences in PRP preparation 
techniques among studies, differences in bone grafting materials combined with PRP 
and differences in investigated time points. In view of this, the current study attempts to 
give more insight into the reasons for this discrepancy and to explain the confusion in 
the literature by exploring the osteogenic capacity of PRP. The aims of this study are:
1. to examine and compare the bone regenerative properties of PRP derived from dif-
ferent species (rat, goat and human) in combination with a synthetic bone substitute;
2. to compare the bone regenerative properties of human bone particles (human bone 
graft) versus human bone particles (human bone graft) combined with human PRP;
3. to compare the bone regenerative properties of human bone particles (human bone 
graft) combined with human PRP versus a synthetic bone substitute combined with 
human PRP.
For this purpose, PRPs and the various materials were installed for implantation pe-
riods of 2 and 4 weeks in critical-sized defects (CSDs) as created in the cranium of 
immunodeficient rats.
Materials and Methods
PRP preparation
Rat PRP (rPRP) was prepared from blood of syngenetic rats according to methods 
described in previous studies [6,7]. Briefly, the whole blood of four male Fisher 344 rats 
was drawn preoperatively via cardiac puncture and subsequently centrifuged at 800 
rpm for 15 minutes (at 25°C). 
Goat PRP (gPRP) was supplied by the Sanquin Blood bank Nijmegen. Briefly, one 
day before surgery, 250 cm3 venous blood was withdrawn from a Saanen goat and 
centrifuged at a transfusion laboratory (Sanquin, Nijmegen, the Netherlands) in various 
cycles to result in goat PRP. 
Human PRP (hPRP) was prepared and supplied by the Sanquin Blood bank, Nijmegen. 
About 500 ml autologous blood of a healthy donor was withdrawn in 70 ml of anticoagu-
lants (citrate-phosphate-dextrose [CPD]) and subsequently cooled to about 22°C. Within 
24 hours of extraction, the blood was separated through centrifugation into erythrocytes, a 
buffy coat (leukocytes and thrombocytes) and plasma. From the buffy coat the leukocytes 
were removed through filtration, and the isolated fraction of platelets was human PRP.
PRP platelet count
To obtain information on the increase in platelet concentration and the final concentra-
tion of platelets in the PRP of the different species, both whole blood and prepared PRP 
were subjected to platelet counts. Platelet counts were performed using a hematology 
analyzer (Advia 120, Bayer B.V., Mijdrecht, the Netherlands).
Bone grafting materials
Synthetic bone substitute
Biphasic calcium phosphate ceramic in form of dense hydroxyapatite/beta-tricalcium 
phosphate (HA/TCP, 60%/40%) particles with a size of 300-500 μm (Camceram, CAM 
Implants, Leiden, the Netherlands) were used as synthetic bone substitute. 
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Human bone graft
Human bone (HB), harvested from a femur during orthopedic surgery, was supplied by 
the Sanquin Blood bank Nijmegen, with the approval of the Ethical committee of the 
Radboud University Nijmegen Medical Center. From it, cortico-cancellous bone graft 
was obtained by means of trephine drill and ground in a bone-mill (Leibinger®, Freiburg, 
Germany) into small particles, each portion weighing 1 gram. 
PRPs activation
Prior to application at the surgical site, all PRP preparations, i.e. rPRP, gPRP and hPRP, 
were activated by the addition of 10% calcium chloride solution and bovine thrombin 
(300 IU) (FibriquikTM Thrombin, BioMerieux Inc., Durham, NC, USA). For each defect, 
150 μl PRP was used and combined with 1 gram of the bone graft material (HA/TCP or 
HB) before activation.
Surgical procedure
Seventy-two healthy, skeletally mature, male, nude Charles River rats (immunodefi-
cient), with an average weight of 250 g, were used in this study. National guidelines 
for care and use of laboratory animals were observed, and the study protocol was ap-
proved by the Animal Ethical committee of the Radboud University Nijmegen Medical 
Center. Each rat received one implant, inserted into an 8 mm wide circular cranial criti-
cal-sized defect (CSD) [17]. In total, six different experimental groups were assigned 
for evaluation periods of 2 and 4 weeks (Table 1).
Table 1:  Type and number of implants/groups as inserted and retrieved  for all evaluation periods
For preparation of the CSDs, anesthesia was induced with 4% Isoflurane by a 
non-rebreather mask and maintained with 2% Isoflurane, 0.4% N2O and 0.4% O2 
during surgery. The animals were premedicated by an intramuscular injection of 
Fentanyl (2.7 ml/kg) to reduce the peroperative pain, and a subcutaneous injection 
of Buprenorphine (150 μg/kg) was applied to reduce the postoperative pain. Before 
surgery, the rat cranium was shaved and swabbed with povidone-iodine. A medial 
sagittal incision extending from the nasofrontal area to the occipital protuberance 
was made and soft tissues were sharply dissected to visualize the cranial perios-
teum. Subsequently, the periosteum was undermined and reflected, exposing the 
parietal bones. A hollow trephine drill (ACE Dental Implant System, Brockton, MA, 
USA) with an outer diameter of 8 mm in a dental hand piece was used to create 
a full thickness CSD into the dorsal part of the parietal bone. During surgery care 
was taken not to damage the dura mater or to puncture the superior sagittal sinus. 
After insertion of the implants, periosteum and overlying skin were closed in sepa-
rate layers with 5-0 and 4-0 Vicryl resorbable sutures, respectively.
Histological preparation
Animals were euthanized at 2 and 4 weeks after surgery by suffocation with carbon 
dioxide. The skin was dissected and the defect sites were removed along with the 
surrounding bone and soft tissues, and fixed in 10% neutral formalin. All speci-
mens (n = 6 per material and evaluation time) were dehydrated in gradual series of 
alcohol and embedded in polymethylmethacrylate (PMMA). After polymerization, 
sections were prepared using a modified diamond-blade sawing microtome tech-
nique (Leica Microsystems GmbH, Wetzlar, Germany). Obtained sections were 
approximately 10 μm thick and stained with methylene blue and basic fuchsin. 
The light microscopical evaluation of all sections was done using an optical micro-
scope (Leica BW, Rijswijk, the Netherlands), and consisted of a complete morpho-
logical qualitative and quantitative description of the tissue response. For evaluation 
of the bone healing process a modified histological scoring system was developed 
(Table 2A) and a comprehensive assessment was performed on three sections per 
cranial specimen. Each section was assigned a score, and from the scores of all 
sections in one group the average score of the group was determined.
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Table 2: Scoring Guides Micro-CT (μCT) scans analysis
Computed tomography of randomly chosen samples (n = 4) was performed using a 
μCT scanner with very high spatial resolution (5 μm corresponding to near 1 x 10-7cubic 
mm voxel size) (Sky Scan 1072, Skyscan NV, Aartsellar, Belgium). Tomographic data 
were acquired by cone-beam acquisition of the specimens (100kV/ 98μA, 25.92 x mag-
nification, 6.5 s exposure, rotation 180 degrees) and reconstructed in 512 x 512 pixel 
matrices by a convolution-back projection procedure. For each sample, a total of 336 
micro-tomographic slices were gained using a slice increment of 25 μm in order to scan 
the whole defect (8 mm) and the surrounding bone. Measurements were stored in 3D 
image arrays of high resolution (1024 x 1024).
From the μCT scan datasets, 3D models were built for visualization and morphometric 
analysis. From the 3D models, the degree of bone union was defined following the 
method developed by Hedberg [18] (Table 2B). 
For the morphometric analysis, database of 320 axial projection skull images was used 
per sample (n = 4). Further, the same approach as described in a previous study by our 
group [7] was applied. Briefly, the defect with the newly formed bone inside was select-
ed as a region of interest (ROI), which by auto-interpolation of layers became volume 
of interest (VOI). Within this VOI, the volume of the HA/TCP particles and the volume 
of the newly formed bone (defined as bone fill %) were calculated. For the HB-groups, 
since it was not possible to distinguish between newly and grafted bone due to their 
similar density, the total bone volume inside the defect was calculated and described as 
bone volume %. For all 3D-measurements grayscale images were used, which were bi-
narised based on histogram calculations (256 grayscale, bone range: 64-225; HA/TCP 
particles range: 0-63). The areas presented in white were identified as image objects 
and all those presented in black were considered as background. The volume of the 
newly formed bone (bone fill in mm3) or total bone volume (in mm3 as defined for HB-
groups) was the total volume of binarised objects within the VOI. The percentage of the 
newly formed bone (bone fill %) or total bone volume % was the proportion of the VOI 
occupied by binarised solid objects. 
Statistical analysis
GraphPad InStat version 3.05 (GraphPad Software, San Diego, CA, USA) was used 
for the statistical analyses of % bone fill and % bone volume data as obtained by μCT 
analyses (i.e.). One-way Analysis of Variance (ANOVA) combined with Tukey-Kramer 
Multiple Comparisons Test was performed. ANOVA assumes that the data are sampled 
from populations with identical standard deviations. This assumption was tested using 
the method of Bartlett. Further, ANOVA assumes that the data are sampled from popu-
lations that follow Gaussian distributions. This assumption was tested using the method 
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of Kolmogorov and Smirnov. Statistical significance was set at p < 0.05.
Statistical analyses on the histomorphometrical and μCT degree of bone union data 
were performed using Poisson regression, as data were not normally distributed. Pois-
son regression was used to elucidate group and time effects. Statistical level of signifi-
cance was set at p < 0.05.
 
Results
General observations
Out of 72 rats used in this study, 4 died during surgery due to severe bleeding caused 
by the rupture of the sagittal sinus (Table 1). The remaining 68 rats had an unevent-
ful recovery and were housed separately to reduce the risk of infection occurrence. 
National guidelines for care and use of laboratory animals were rigorously followed. 
No clinical signs of infection or inflammatory response were seen, and all rats gained 
weight during the implantation period. 
PRP preparations
Platelet counts in rat, goat and human PRPs showed substantial increase above the 
baseline number of platelets in the whole blood of the species as presented in Table 3.
Table 3: Platelet count in PRPs
Histological descriptive and quantitative evaluation 
Two weeks results
After 2 weeks of implantation, only minor bone formation was seen in all groups, which 
occurred mainly at the defect edges (Figure 1). 
Figure : Light micrographs of PMMA embedded specimens showing bone formation in all groups after  and  
weeks (1.6 x magnification), bar = 625 μm     
Occasionally, some bone ingrowth from the dura site was detected in both graft alone 
groups (HA/TCP and HB) and both hPRP groups (HA/TCP+hPRP, HB+hPRP). Within 
the defect, bone grafts (HA/TCP and HB) in all groups with and without PRP were found 
completely surrounded by fibrous tissue (Figure 2), and occasionally, start of guided 
bone formation around the particles was noticed, without any preference for a particular 
group. At the defect edges, direct bone to implant contact without any fibrous tissue 
interface was found mainly in the groups with HB (HB and HB+hPRP). In contrast, only 
half of the sections of HA/TCP and HA/TCP combined with different PRPs showed 
direct bone to implant contact at one defect border. 
The data obtained with the histological scoring system are depicted in Figure 3A. Sta-
tistical analyses indicated that after 2 weeks of implantation, rat, goat and human PRP 
combined with HA/TCP showed almost comparable scores in each category related 
to the bone healing process, such as hard tissue response at bone-implant interface, 
hard tissue response in between the particles/ bone fillers, bone fill in vertical direction, 
defect closure and direction of bone formation. 
Overall, defects filled with hPRP and bone particles (HB+hPRP) showed slightly better 
scores than those filled with HB alone. However, this difference was not statistically 
significant.
hPRP in combination with HB (HB+hPRP) showed comparable scores to hPRP in com-
bination with HA/TCP (HA/TCP+hPRP) for most of the parameters (Figure 3A). Only 
for the defect closure, the scores of HB+hPRP were significantly higher than those of 
HA/TCP+hPRP group (p < 0.05).
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Figure : Histological semi-quantitative evaluation
A) after  weeks B) after  weeks
Four weeks results
After 4 weeks of implantation, light microscopical analysis demonstrated clear bone 
formation at the defect edges and at the dura site in all groups (Figure 1). Only one 
specimen of the HA/TCP+rPRP group showed the start of new bone formation from the 
periosteum. Generally, at higher magnification no differences in morphology of the newly 
formed bone were observed among the various groups. Newly formed bone in all slides 
appeared as a woven structure without preferred orientation of the collagen fibers in the 
bone matrix and an abundance of osteoblasts and small blood vessels was observed. 
No signs of bone remodeling or presence of osteoclast-like cells were seen, neither were 
signs of inflammation present. However, the bone formation process appeared to be 
more active in the HB group, where newly formed bone was bridging the human bone 
particles (Figure 2). Bone bridging was found at both defect borders in all groups, except 
for the HA/TCP+rPRP, where in half of the specimens a connective tissue layer still filled 
the gap between the defect edge and the inserted HA/TCP particles. Tissue formation 
in between the graft materials (HA/TCP and HB) with and without PRP showed hardly 
any difference among all groups, and consisted of some bone and fibrous tissue. For all 
groups with HA/TCP particles with and without PRP, newly formed bone was guided by 
their outer surfaces (Figure 2). This guidance was at best to be seen in the HA/TCP and 
HA/TCP+hPRP group. Further, HA/TCP, HA/TCP+hPRP, HB and HB+hPRP particulates 
were directly embedded in bone without an intervening fibrous tissue layer. In contrast, in 
the HA/TCP+gPRP and HA/TCP+rPRP groups, bone substitute particles were still sur-
rounded by a thin fibrous tissue layer. 
Although no specific staining for blood vessels was performed, gross evaluation revealed 
comparable neovascularization in all groups. 
The data obtained with the histological scoring system are depicted in Figure 3B. Statisti-
cal analyses indicated that after 4 weeks of implantation, rat, goat, and human PRP com-
bined with HA/TCP, and HA/TCP alone showed similar scores for each parameter. Again, 
scores of HB+hPRP were comparable to those of HA/TCP+hPRP, except for defect clo-
sure, which was significantly higher for the HB+hPRP group (p < 0.05). Defects filled with 
HB+hPRP showed comparable scores with HB alone. Results of HB+hPRP were slightly 
superior over the results of HA/TCP+hPRP, though not significantly different.
In addition, all groups showed a significant increase from 2 to 4 weeks for the following 
parameters: hard tissue response at bone-implant interface (p < 0.001), direction of 
new bone formation (p < 0.05) and hard tissue response in between the particles/ bone 
fillers (p < 0.001). 
μCT analysis
Degree of bone union
Two weeks results
3D models demonstrated bone formation in all groups after 2 weeks of implantation. 
For the HA/TCP, HA/TCP+gPRP and HA/TCP+rPRP, the degree of bone union was 
in the form of a few bony spicules dispersed through the defect, whereas for the HA/
TCP+hPRP group bony bridging at the defect edges was observed.
All data dealing with the degree of bone union are presented in Figure 4. Scores of 
HB+hPRP group exceeded in general the scores of HB group and HA/TCP+hPRP, 
however, this was not significant. Statistical analyses indicated a significant difference 
for degree of bone union in favour of HB+hPRP compared to HA/TCP, HA/TCP+gPRP, 
and HA/TCP+rPRP groups (p < 0.01).
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Figure : Semi-quantitative evaluation for degree of bone union:
 - bony bridging at longest point,
 - bony bridging over partial length, 
 - bony bridging at defect edges, 
 - few bony spicules dispersed through the defect.
3D reconstructions revealed that the addition of hPRP to the HB particles resulted in 
bony bridging over the partial length of the defect, whereas when HB particles were 
applied alone, bony bridging was limited to the defect edges.
Four weeks results
At 4 weeks, of implantation, 3D modeling and statistical analyses demonstrated no 
change in the degree of bone union in all groups compared to the scores after 2 weeks. 
Briefly, HB+hPRP showed the highest degree of bone union, which was significant 
compared to HA/TCP, HA/TCP+gPRP, and HA/TCP+rPRP (p < 0.01). No difference 
was observed between HA/TCP+hPRP, HB and HB+hPRP.
Bone Volume
Two weeks results
After 2 weeks, the amount of newly formed bone (% bone fill) was similar for HA/TCP, 
HA/TCP+gPRP and HA/TCP+rPRP, i.e. ± 7% (Figure 5A), while the HA/TCP+hPRP 
showed significantly more bone fill, i.e. 14% ± 2 (p < 0.001). 
The total bone volume for HB+hPRP (18% ± 2) was significantly higher than the bone 
volume for HB (14% ± 1) (p < 0.01). (Figure 5B).
Figure 5: μCT morphometrical analysis: 
A) % of bone fill B) % of total bone volume
Four weeks results
At 4 weeks of implantation, no significant differences were observed in the amount of 
newly formed bone between all HA/TCP groups (Figure 4). 
At 4 weeks, the total bone volume for HB+hPRP (20% ± 1) was comparable to HB 
(17% ± 3).
Discussion
This study was performed to provide an explanation for the existing confusion in the li-
terature regarding the efficacy of PRP treatment, as well as to give more insight into the 
effect of PRP on bone regeneration. All PRP preparations as carried out in this study 
met the recommendations in terms of preparation technique (centrifugation speed, 
force and time) and platelet concentration. In view of the correlation between platelet 
count and growth factor levels [2], it is likely that the amounts of GFs as released from 
rat and goat PRP were not comparable with those of human PRP. This suggestion is 
supported by the findings of Trowbridge [19] that rat mean platelet count is significantly 
higher than human, whereas rat mean platelet volume is significantly lower than hu-
man. In view of the lower rat platelet volume and the fact that GFs are stored in plate-
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lets’ α-granules, variation in concentration of GFs within rat and human platelets could 
be expected. In addition, PRP preparation from animal blood is not a standardized 
procedure such as PRP preparation from human blood. Therefore, critical effective 
amounts of platelets in PRP for different animal species, levels of GFs in different ani-
mal species and similarity in their mechanisms of action have still to be defined. Until 
then, all comparisons between human and animal PRP preparations/studies, including 
the present study, should be interpreted carefully.
In basic research, small animals, i.e. rodents (rat, rabbit) are routinely used as models 
to evaluate the biological potential of new technologies, while large animals (dogs, 
sheep, goat, pig) are used in a subsequent step to evaluate the clinical potential and 
application of such new technologies. Therefore, to obtain a complete overview of the 
treatment potential of an emerging technology, both small and large animal studies 
have to be performed. During last experimental stage, the obtained animal data have to 
be extrapolated to a human situation, which is done in human clinical trials. Frequently, 
this extrapolation of the experimental animal data to human application is complex. In 
view of this, it appeared appropriate to select PRPs from two representative animal 
models on which PRP has been studied i.e. one small (rat) and one large (goat), and 
to compare them (rat PRP and goat PRP) with human PRP. Nude Charles River rats 
were selected as experimental models due to their immunodeficiency, which enabled 
the use of PRP derived from different species (i.e. rat, goat, human PRP). Moreover, in 
immunodeficient rats the requirement of PRP as an autologous preparation [2] can be 
considered as fulfilled, as well as bone harvested from human beings can be regarded 
as an autologous graft. 
In the current study, no effect of rat PRP on bone formation was found. This result 
corroborates our previous rat PRP studies [6,7] as well as the cranial defect-rat PRP 
studies of Pryor [20,21]. In contrast, in the study of Messora [22], rat PRP was reported 
to significantly enhance bone healing in calvarial CSDs after 4 and 12 weeks. However, 
it has to be noticed that the study design in this experiment was inappropriate to draw 
conclusions on the effect of rat PRP. The authors used rat PRP combined with rat plate-
let-poor plasma (rat PPP) and compared their effects to rat blood. 
The current study failed to show any effect of goat PRP on bone formation. These re-
sults are consistent with the study of Mooren [23], where goat PRP was also not able 
to enhance neither early nor late bone healing. In the study of Mooren, goat PRP with a 
comparable concentration of platelets as in our study (i.e. 4-5 fold increase over plate-
lets baseline number) was applied in bone defects created in the skull of goats. Further, 
autologous goat bone particulate was used as grafting material and appropriate control 
defects were included in the experimental design. Nevertheless, the histologic and 
histomorphometric examinations showed no effect of goat PRP after 1, 2, 6, and 12 
weeks of implantation. The authors refer to contradictory information about the baseline 
concentrations of platelets in goats [24-26]. As a consequence, it cannot be excluded 
that their concentration of PRP was just too low to induce any effect at all. Since in the 
current study goat PRP was prepared using a similar protocol, it can be speculated that 
the goat PRP in our experiment was also not sufficiently concentrated. 
Our histological and μCT data revealed an early beneficial effect of human PRP on 
bone healing. These findings support the suggested action mode of PRP. The active 
secretion of GFs from the platelets begins within 10 min after blood clotting and more 
than 95% of the presynthesized GFs in the α-granules of the platelets are secreted 
within 1 hour. After the initial burst release of PRP-related GFs, platelets synthesize 
and secrete additional GFs for the remaining 10 days of their life span [2]. Therefore, 
PRP is supposed to affect the early bone healing, rather than late bone formation. 
The observed enhanced effect of human PRP, when combined with human bone graft 
material compared to a combination with a synthetic bone substitute, can also be ex-
plained by the mechanism of action of PRP. According to Marx, PRP is postulated to 
exert its effect on living cells [1]. Consequently, when PRP is used together with syn-
thetic, non-cellular bone substitutes less promotion of bone formation compared to the 
use with bone graft material could be expected. The beneficial effect of PRP applied 
in combination with a synthetic bone substitute, will depend on the amount of resident 
osteoprogenitor cells at the bone defect site. Occasionally, it is supposed that osteo-
conductive materials can obscure the true effect of PRP [21,27]. 
The use of various analytical techniques, like histology and μCT, to evaluate the pro-
cess of bone formation is considered to provide the most complete and reliable data 
[18]. A morphological analysis of μCT 3D models gives more comprehensive and reli-
able information than histological sections alone. Histological sections are 2D images 
and always limited in number (3 sections per sample vs. 320 sections per sample for 
the μCT), which partially explains the slight differences between the current histological 
and μCT results. In addition, μCT facilitates the histomorphometrical analysis of bone 
fill and bone ingrowth [6]. In view of this, it has to be noticed that the histological “bone 
fill in vertical direction” is a morphometric paramater indicating the appearance of the 
newly formed bone, whereasthe measured μCT “bone fill” is a volumetric parameter 
demonstrating the amount of the newly formed bone. Evidently, in the current study, 
the correlation between the histological and μCT results were proven once again. The 
results on defect closure, a histological 2D parameter, coincided with the results for 
both bone union and bone volume (3D μCT parameters).
Despite the beneficial effect of human PRP in combination with human bone graft, 
the amount of bone formation was still limited and less than expected for “autologous” 
material. Probably, this is due to the source of the graft material, as the human bone 
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was harvested during surgery for installation of a hip implant. Patients subjected to this 
kind of surgical intervention are prone to poor bone quality in the surgical area, since 
the most common indication for total hip replacement surgery is osteoarthritis. Osteo-
arthritis together with osteoporosis are known as age-associated ‘degenerative dis-
eases’. It is known that with increasing age there is a relative decline in trophic factors 
(e.g. oestrogen, IGF-1, vitamin D) favouring local expression of molecules (interleukins, 
TNFα), which decrease osteoblast activity, increase osteoclast activity, and reduce the 
differentiation potential of bone marrow stem cells [28]. Therefore, it can be speculated 
that bone graft harvested from a patient suffering from age-associated degenerative 
disease posseses inferior osteogenic properties. In addition, it can be suggested that 
the size of the particles also plays a role in the observed limited effect. It is known that 
too large particles hinder adaptation of the graft material to the defect site. Since in 
the μCT 3D models the particles appeared to be not so uniformly distributed as the 
HA/TCP,  an inappropriate size of the particles for this particular type of defect cannot 
be excluded. 
Within the limitations of this study (in terms of animal species and used PRP prepara-
tion technique), the PRP derived from the used animal species was shown to have no 
effect on bone regeneration neither at early nor at late time points. In contrast, human 
PRP seemed to have a beneficial effect on bone regeneration. These findings together 
with observation that the majority of animal studies in the literature fail to prove an 
osteopromotive effect of PRP, raises the question to what extent animal studies can be 
used to draw conclusions on the potential of human PRP. In addition, there is serious 
doubt that animal PRP and its preparation is completely comparable to human PRP. On 
the other hand, some evidence exists that PRP has a beneficial effect on maxillo-facial 
bone regeneration, but this proof is weak [15,16, 29]. In view of this, it has to be recom-
mended that future efforts be focused on well-designed human randomized-controlled 
clinical trials to provide complete support for the clinical application of PRP instead of 
the continuation of animal studies.
Conclusions
In summary, our study showed that rat and goat PRP had no effect on bone formation, 
neither at early nor at late time points. Human PRP combined with human bone graft 
material resulted in an increased osteogenic effect over bone graft material alone after 
2 weeks of implantation. At 4 weeks, this additional effect of human PRP was not ob-
served. Finally, the combination of human PRP with human bone graft material seems 
to be more effective than the use of human PRP with a synthetic calcium-phosphate 
based bone substitute. 
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Introduction
Autogenous bone is still considered to be the “golden standard” for bone augmen-
tation. However, due to the known limitations of autogenous bone grafting, such as 
donor site morbidity and limited supply, increasing efforts focus on the development 
of bone substitutes. In order to create a bone graft, which is comparable or superior 
to bone, allografts are combined with osteoinductive substances, such as growth fac-
tors. Transforming growth factor-β1 (TGF-β1) is a member of TGF-β superfamily, which 
regulates key aspects in bone metabolism (Massagué J. 1990). It affects osteoblast 
differentiation, matrix formation, and mineralization. Furthermore, it exerts its functions 
both during embryogenesis and in adult organisms, orchestrating complex phenomena 
such as inflammation and tissue repair (Roberts and Sporn 1993). Studies have shown 
that TGF-β1 supplied to a variety of biomaterials is able to enhance bone formation in 
vivo, depending on concentration and application method (Okuda et al., 1995; Sumner 
et al., 1995; Lind et al., 1996). Consequently, TGF-β1 is an appealing factor for use in 
clinical procedures for bone augmentation.  
As mentioned above, various materials have already been used for local delivery of 
TGF-β1, including calcium phosphate (CaP) ceramics (Okuda et al., 1995; Sumner 
et al., 1995; Lind et al., 1996). This material has been selected for bone replacement 
and augmentation due to its excellent bone behavior. The shortcomings of the prefabri-
cated CaP ceramics, such as lack of shaping and difficult delivery to the defects, have 
been overcome by the development of injectable CaP cements (Ooms et al., 2005). 
Injectable self-setting cement can fill macroscopic as well as microscopic bone defects. 
Cements of this kind may be resorbed, allowing gradual replacement by host bone 
(Jansen et al., 1995). To promote degradation and tissue ingrowth injectable CaP ce-
ments have been combined with PLGA microspheres (Ruhe et al., 2003). Additionally, 
these degradable PLGA microspheres provide a method for delivery of bone formation 
promoting proteins, like TGF-β1. Such an injectable composite has been developed by 
our group and comprehensively studied in vitro and in vivo (Ruhe et al., 2003; 2005; 
2007). However, the direct mode of application in a bone augmentation model has not 
been evaluated yet.
In view of the above mentioned, the aim of this study was to examine the bone aug-
mentation properties of an injectable PLGA/CaP composite and to evaluate the addi-
tional effect of loading the composite with TGF-β1 in a rat model.
Materials and Methods
Materials
The calcium phosphate cement Calcibon® (Biomet Merck, Darmstadt, Germany) was 
used in this study. The cement powder consisted of 62.5% α-TCP (alpha tri-calcium 
phosphate), 26.8% CaHPO4, 8.9% CaCO3 and 1.8% PHA (precipitated hydroxyapa-
tite). An aqueous solution of 1 % Na2HPO4 was used as a liquid component with a 
liquid/powder ratio of 0.35 ml/g. Low-molecular weight poly (D, L-lactic-co-glycolic acid) 
(PLGA) Purasorb® was provided by Purac, Gorinchem, the Netherlands. Human rh-
TGF-β1 was supplied by R&D Systems, Abingdon, UK. 
Preparation of PLGA microspheres 
PLGA microspheres were prepared using a water-in-oil-in-water (w/o/w)-double emulsion 
solvent evaporation technique, as described previously by Ruhe et al. (Ruhe et al., 2003). 
Briefly, 1.4 g of low molecular weight (LMW) PLGA was dissolved in 2 ml of dichlorometh-
ane (DCM) inside a 50 ml poly propylene (PP) tube. 500 ml demineralized water (ddH2O) 
was added while vortexing vigorously for 1 min, subsequently adding 6 ml of a 0.3% poly-
vinylalcohol (PVA) solution. Vortexing was continued for another 1 min. The content of the 
50 ml tube was transferred to a stirred 1000 ml beaker and another 394 ml of 0.3% PVA 
was added slowly. This was directly followed by adding 400 ml of a 2% isopropylic alcohol 
(IPA) solution. The suspension was stirred for 1 hr. The spheres were allowed to settle 
for 15 min and the solution was decanted. The suspension left was centrifuged, and the 
clear solution at the top was decanted. Five ml of ddH2O was added, the spheres were 
washed, centrifuged and the solution was aspirated. Finally the spheres were frozen, 
freeze-dried for 24 hr and stored under argon at -20°C. 
Adsorption of TGF-β1 on PLGA microspheres
One μg of recombinant human TGF-β1 (rh-TGF-β1) was dissolved into 800 μl of 0.1% 
acetic acid and added to 1.0 g of microspheres, after which the TGF-β1 was freeze-
dried onto the microspheres. The entrapment efficiency of the protein was determined 
by normalizing the amount actually entrapped with the amount added to the fabrication 
process. 
Preparation of PLGA/CaP composites
Composites were made by adding PLGA microspheres to the CaP cement in a weight 
ratio 20/80 PLGA/CaP cement. The cement powder was sterilized by gamma radiation 
with 25 kGy (Isotron B.V., Ede, the Netherlands) and the cement liquid was filter-steril-
ized (0.2 μm filter). Firstly, 256 mg CaP cement powder provided with 64 mg PLGA 
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microspheres was added to a 2 ml plastic syringe (Sherwood Medical Monojet 2 ml, 
Schwallbach, Germany). The mixture was shaken vigorously for 15 sec using a Si-
lamat® mixing apparatus (Vivadent, Schaan, Liechtenstein). Subsequently, 125 mg 1% 
Na2HPO4 was applied to the mixture, shaken again for 15 sec and then delivered by 
means of the syringe to the surgical site. PLGA/CaP composites provided with TGF-β1 
were made by adding a fraction of TGF-β1 adsorbed PLGA microspheres to a fraction 
of as-prepared PLGA microspheres, followed by the same procedure as described for 
the unloaded composites. The average amount of delivered material was 60 mg and 
the growth factor loaded composites contained 200 ng TGF-β1.
Surgical procedure
For the animal experiment, twenty-four healthy, skeletally mature male Wistar rats, 
with an average weight of 250 g, were used. National guidelines for care and use of 
laboratory animals were observed, and the Animal Ethical committee of the Radboud 
University Nijmegen Medical Center approved the study protocol. In total, 48 com-
posite implants were placed; each animal received 2 implants from the same group 
on its parietal cranial bone for evaluation periods of 2, 4 and 8 weeks (n = 8 for each 
material and evaluation time). 
Anesthesia was induced with 4% Isoflurane by a non-rebreather mask and maintained 
with 2% Isoflurane, 0.4% N2O and 0.4% O2 during surgery. The animals were premedi-
cated by an intramuscular injection of Fentanyl (2.7 ml/kg) to reduce the operative pain, 
and a subcutaneous injection of Buprenorphine (150 μg/kg) was applied to reduce the 
postoperative pain. 
Before surgery, the rat cranium was shaved and swabbed by iodine. A medial sagittal 
incision extending from the nasofrontal area to the occipital protuberance was made 
and soft tissues were sharp dissected to visualize the cranial periosteum. Subsequent-
ly, the periosteum was undermined and reflected, exposing the parietal bones. A hollow 
trephine bur (ACE Dental Implant System, Brockton, MA, USA) with an outer diameter 
of 5 mm in a dental hand piece was used to mark the position of two augmentation 
sites on the parietal bone, aside from the sagittal sinus. The trephine bur did no pen-
etrate into the whole thickness of the skull, but was stopped just in the upper part of the 
cortical plate next to the periosteum. Within the marked areas the cranial surface was 
scratched in order to remove part of the cortical bone and to get exposure of osteogenic 
cells. Afterwards, a silicon mold with a diameter of 5 mm, specifically designed for this 
purpose, was placed on the cranium and the PLGA/CaP composite was injected (Fig-
ure 1). In this way, implants in the form of discs were created, with a diameter of 5 mm 
and a height of 2 mm. After setting of the composite, the mold was removed and the 
periosteum and overlying skin were closed in separate layers with 5-0 and 4-0 Vicryl 
resorbable sutures, respectively.
Figure : Rat model for bone augmentation: 
A) defect, B) silicon mold, C) PLGA/CaP composite in mold, D) PLGA/CaP composite after setting and 
removal of the mold.
Histological preparation
The animals were sacrificed 2, 4, and 8 weeks after surgery using an overdose of car-
bon dioxide. The skin was dissected and the defect sites were removed along with the 
surrounding bone and soft tissues, and fixed in 10% neutral formalin for one week. Half 
of the specimens (n = 4 per material and evaluation time) were dehydrated in gradual 
series of alcohol and embedded in polymethylmethacrylate (PMMA). Before the em-
bedding procedure, samples were cut exactly through the middle of the implants to 
secure that the microtome sections were made in the area of interest and the same re-
gion was analyzed for each sample. After polymerization, sections were prepared using 
a modified diamond-blade sawing microtome technique (Leica Microsystems GmbH, 
Wetzlar, Germany). Obtained sections were approximately 10 μm thick and stained with 
methylene blue and basic fuchsin. The remaining specimens (n = 4 per material and 
implantation time) were decalcified for 2 weeks in Formical-2000 (Immunodiagnostika 
& Biotech GmbH, Berlin, Germany) and then embedded in Paraplast paraffin (Klinipath 
B.V., Duiven, the Netherlands). Sagittal microtome sections were made, 5 μm in thick-
ness, which were stained with hematoxylin-eosin and immunohistochemically using an 
antibody against CD68 (Macrosialin (Janeway et al., 1999) to detect inflammatory cells 
including monocytes, macrophages, and neutrophils. Again, before the embedding pro-
cedure, samples were cut exactly through the middle of the implants. 
The light microscopical evaluation of all sections was done using an optical microscope 
(Leica BW, Rijswijk, the Netherlands), and consisted of a complete morphological de-
scription of the tissue response to different implants as well as of histomorphometrical 
analysis. 
Histomorphometry
For the histomorphometrical analysis, a Leica Qwin Proimage analysis system (Leica 
BV, Rijswijk, the Netherlands) was used. Sections were digitized at low magnification 
(2.5 x) and measurements were done on three sections per cranial specimen. All PMMA 
sections were used for evaluation of bone response and all paraffin sections for assess-
ment of inflammatory reaction.
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To quantify the amount of bone augmentation, newly formed bone, as stained and dis-
cerned by its woven structure and location, was marked manually and its area was 
measured. Afterwards, this ROI was subtracted from the whole area of the implant. From 
these two data, the amount of bone formation (%) was calculated. 
In order to measure the contact length between the implants and the bone, lines were 
drawn manually at the direct interface between the composites and newly formed bone. 
The sum of these intersections was calculated and interpreted as contact bone/compos-
ite length. 
Further, the intensity of the inflammatory response around the implants was quantified. 
For this purpose pictures with higher magnification (i.e. 10x) were used. The presence 
of macrophages was detected with anti-CD68 staining and subsequently digitized by a 
computer programme in the region of interest (implant + surrounding tissue; ROI). The 
areas with positive anti-CD68 staining were given as a percentage (%) of the total ROI. 
Statistical analysis
For the statistical analyses, GraphPad InStat program (GraphPad Software, San Di-
ego, CA, USA) was used. One-way Analysis of Variance (ANOVA) was performed on 
the data obtained from the histomorphometric analyses. ANOVA assumes that the data 
are sampled from populations with identical standard deviations. This assumption was 
tested using the method of Bartlett. Further, ANOVA assumes that the data are sampled 
from populations that follow Gaussian distributions. This assumption was tested using 
the method of Kolmogorov and Smirnov. In addition, a Tukey-Kramer Multiple Compari-
sons Test was done. Differences were considered to be significant when p < 0.05.
Results
General observations
The injection of the composite into the silicon mold placed on the scratched cranial 
surface went without complications. The setting time of both loaded and unloaded com-
posites was about 10 min. Setting and handling properties of the composites were 
influenced by the presence of blood. When the composite was injected on dry, good 
isolated cranial surfaces the setting time was shorter, the composite was easily shaped, 
and after removal of the mold the implant was secured more stable. Mixing with blood 
affected the handling properties of the composites and made them more fragile. In 
addition, the composites loaded with TGF-β1 appeared to be more fragile after setting 
than the unloaded composites, as indicated by easy cracking.
During the implantation periods all animals remained in good health. At sacrifice, mac-
roscopic signs of inflammation and adverse reaction were apparent around loaded as 
well as unloaded implants predominantly after 2 and 4 weeks. After 8 weeks, the signs 
of inflammation disappeared. Upon retrieval, all implants in both groups were in situ 
and surrounded by a fibrous capsule. The capsule thickness differed between different 
time points with a tendency of reduction for the later periods. No differences between 
the loaded and unloaded composites were observed. 
Descriptive histology
Histological examination of PMMA embedded samples revealed new bone formation in 
both groups at all time points. Newly formed bone was more abundant at 4 and 8 weeks 
in comparison to its amount at 2 weeks (Figure 2). Bone formation was observed at the 
defect margins and along the lower part of the cement at the side of the cranium. No 
bone formation was seen from the periosteum side on the top of the implants, as well 
as throughout the implant. 
Figure : Light micrographs of PMMA embedded specimens showing bone augmentation at different time 
points (2.5x magnification) 
At higher magnification, newly formed bone revealed thin trabeculae and large mar-
row spaces filled with fat tissue and haematopoietic cells. In addition, a direct contact 
between the composites and newly formed bone, without any fibrous tissue interface, 
was apparent in both experimental and control groups (Figure 3). 
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Figure 3: Histological section of PMMA embedded specimen (10x magnification). 
A) unloaded PLGA/CaP composite B) TGF-β1 loaded PLGA/CaP composite 
Guided bone formation is visible with direct contact composite - newly formed bone without any fibrous tissue inter-
face. Dash line in yellow indicates the transition between the newly formed bone and the old bone. OB - old bone, 
NB - newly formed bone, C – composite.
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Furthermore, implants managed to stay in place during all investigation periods. How-
ever, the integrity of the composite structure appeared to be affected. Fractures, as 
observed inside the implants, were filled with fibrous tissue and inflammatory cells. 
Signs of inflammation were at best visible in the paraffin sections stained for CD68. 
The inflammatory infiltrate, consisting of macrophages and lymphocytes, surrounded 
the implants and penetrated into the composite structure. In the course of time a sub-
stantial decrease in the inflammatory response was observed in both groups (Figure 
4). Together with the decrease in inflammation, a consolidation of the implant fragments 
and their incorporation in the bone tissue was noticed.
Figure 4: Light micrographs of paraffin sections stained for CD68 showing the inflammatory response at different 
time points (2.5x magnification).
Paraffin sections stained with hematoxylin-eosin did not provide any additional informa-
tion to the PMMA sections.
Histomorphometry
The amount of newly formed bone was almost the same for both experimental and 
control groups after 2 and 4 weeks. At 8 weeks, there was more bone formation in the 
group of TGF-β1 loaded implants (18.5% ± 3) than in the group of the unloaded ones 
(7.2% ± 5), which was statistically significant (p < 0.05; Figure 5).
 
The contact length between the composites and newly formed bone increased in time. 
At 2 weeks TGF-β1 loaded samples showed significantly better bone contact than un-
loaded controls (19 mm ± 7 vs. 2.7 mm ± 4 and p < 0.05). After 4 and 8 weeks, no 
difference in the contact length was observed between the groups (Figure 6).
The amount of inflammation after 2 weeks was substantial for both groups. How-
ever, after 4 weeks it decreased to 9.0% ± 2 for the TGF-β1 loaded implants and 
to 13.3% ± 2 for the controls. This difference between the groups appeared to be 
statistically significant (p < 0.01). At 8 weeks a minor inflammation was observed 
in both groups (Figure 7).
Figure : Histomorphometric mea-
surements of bone formation in per-
centage for all evaluation periods. 
Asterisk (*) indicates statistically 
significant difference (p < 0.05).
Figure : Histomorphometric mea-
surements of composite/bone con-
tact length for all evaluation periods. 
Asterisk (*) indicates statistically 
significant difference (p < 0.05).
Figure : Histomorphometric 
measurements of the amount of 
inflammation in percentage for all 
evaluation periods. Asterisk (**) 
indicates statistically significant 
difference (p < 0.01).
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Discussion
The present study demonstrates that the used injectable PLGA/CaP (20/80) composite 
stimulated bone augmentation in a rat model. Moreover, the addition of TGF-β1 to the 
composite significantly enhanced new bone formation at 8 weeks when compared to the 
control (i.e. unloaded PLGA/CaP composite). The osteopromotive effect of TGF-β1 has 
been demonstrated in many studies  (Arnaud et al., 1994; Zhou et al., 1995; Sumner et 
al., 1995; Lind et al., 1996; Beck et al., 1991; 1993; Moxham et al., 1996). There are, how-
ever, studies that describe absent or even adverse effect of TGF-β1 on bone formation 
(Lind et al., 1994; Aspenberg et al., 1996). Since it is known that follow-up period, as well 
as animal species may play role in this aspect (Janssens et al., 2005), it has been decided 
to compare the outcomes of the current study with similar experimental studies. Our find-
ings corroborate the results of Vuola et al. (Vuola et al., 2002). In their rat cranial model 
TGF-β1 loaded coral based implants enhanced bone regeneration, and the amount of 
newly formed bone was also not significantly higher compared to the controls until the 
8th week. The authors suggested that the influence of TGF-β1 on bone formation lasted 
several weeks and diminished with age. In the study of Vuola et al. 6-8 months old rats, 
weighing 550-560 g, were used. In our study the experimental animals were younger, yet 
skeletally mature, and with a weight of approximately 250 g. Further, the concentration of 
TGF-β1 incorporated in our composites (200 ng) was much lower than that used in the 
study of Vuola (1, 2 and 25 μg).
The effect of TGF-β1 on bone formation is known to be dose dependent, however it has to 
do more with an optimal than with a maximal dose (Beck et al., 1993). For example, Blom 
et al. (Blom et al., 2001) reported enhanced bone formation for the same implantation 
period with very low concentrations of TGF-β1 (10 ng and 20 ng) incorporated in a similar 
type of CaP cement. In the current experiment enhanced bone formation was observed 
also with a lower TGF-β1 dose than applied in similar studies (Okuda et al., 1995; Bosch 
et al., 1996). Therefore, it can be suggested that the amount of TGF-β1 needed to exert 
an effect may depend on the type of carrier used. 
Delivery systems are of great importance when growth factors are utilized to enhance 
bone-healing process (Puolakkainen et al., 1995). In previous studies (Ruhe et al., 
2003, 2005) it was demonstrated that: (a) PLGA/CaP composite is a suitable carrier 
for GFs, and (b) the method of loading GFs on the scaffold (freeze-drying on top of the 
PLGA microspheres) does not affect their osteoinductive properties. However, the high 
protein binding affinity of CaP cement must be taken into account. Therefore, it can 
be hypothesized that after release from the PLGA microspheres, TGF-β1 may have 
bound to the CaP cement resulting in a delayed release from the composite. This might 
explain why no increase in bone formation was seen after 4 weeks for TGF-β1 loaded 
materials compared to the controls. At the moment, it is still unclear whether the TGF-
β1 as bound to the CaP cement has maintained its osteopromotive properties. We have 
to notice that this has to be an issue of investigation.
It has also to be emphasized that the effect of TGF-β1 on bone formation differs among 
species. In general, studies using rodents and primates as experimental models do not 
report so favorable outcomes concerning the osteopromotive ability of TGF-β1 compared 
to studies using dogs (Janssens et al., 2005).
In the current study the release kinetics of the TGF-β1 from the PLGA/CaP composite 
was not examined. On the other hand, similar designed PLGA/CaP composites were 
recently used in another study for the delivery of enamel matrix derivate (EMD) (Pla-
chokova et al., In press). An in vitro assay revealed that after 4 weeks only 60% of EMD 
was released from these scaffolds, and this sustained release continued as observed 
during extended follow-up periods. In view of this, it can be speculated that such a re-
lease pattern is too slow for TGF-β1 to support early bone development. Therefore, the 
TGF-β1 promoted bone formation after 4 weeks was enhanced but not statistically sig-
nificant compared to the control. Nevertheless, it must be taken into account that EMD 
and TGF-β1 are completely different proteins. Additionally, the EMD release profile was 
determined in vitro, which is known to differ from the in vivo situation. In this regard, in 
vitro and in vivo TGF-β1 release profiles from PLGA/CaP composites are necessary to 
prove the above-mentioned hypothesis. 
Another reason for lack of significant difference in the amount of newly formed bone 
between the groups at 2 and 4 weeks could be the material used as a control. The 
PLGA/CaP composite material has already demonstrated excellent bone regenera-
tive capacity in previous rat studies (Plachokova et al., In press). Therefore, it appears 
unlikely that an osteopromotive agent, such as TGF-β1, could increase substantially 
its initial effect on bone formation, especially when applied in such a low concentration 
(i.e. 200 ng).
The PLGA/CaP composite material is a fast-setting type of cement, which still provides 
sufficient time for molding and contouring in order to achieve precise adjustment to the 
defect or augmentation site (Ginebra et al., 1994; Kairoun et al., 1997). The initial mate-
rial/bone (material/implant) contact is of utmost importance for integration of the filler 
material and early onset of remodeling. In case of discontinuity in the material/bone 
(material/implant) interface, fibrous tissue ingrowth between the filler and the bone/im-
plant will delay bone formation and might result in failure. To estimate material/bone 
interface, bone contact measurements were performed. In the current study, the bone 
contact length for the PLGA/CaP composite increased from 2.76 to 39.63 mm during 8 
weeks of implantation. Moreover, TGF-β1 loading resulted in an additional increase of 
the initial bone contact, since this material showed significantly higher values of con-
tact length at 2 weeks in comparison with the unloaded material. The reason for this 
significantly increased bone contact in favor of TGF-β1 loaded composites appears to 
be unknown and will be a subject of a future investigation. 
Concerning the material application method in this study, direct injection of the PLGA/
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CaP composite without fixation was chosen due to the close resemblance of this mode 
of application to the final clinical approach. Nevertheless, it should be taken into account 
that lack of rigid fixation of the implants to the skull can have influenced bone formation. 
Rigid fixation is known to decrease movement and shear forces on the graft, thereby 
improving revascularization and resulting in earlier bone apposition and improved os-
teoconduction (La Trenta et al., 1989; Lin et al., 1990; Phillips and Rahn 1990). 
Finally, at two weeks of implantation, a serious inflammatory response to the PLGA/
CaP material was observed. In view of this, it has to be noticed that the mechanical 
properties of the PLGA/CaP composite are limited. As a consequence, tight closure of 
the periosteum and subcutaneous tissue over the implants can have caused a high 
pressure resulting in the occurrence of fractures in the cement material. These frac-
tures can be associated with the appearance of small CaP particles. Orthopedic im-
plant studies have already highlighted that CaP particles can induce an inflammatory 
response (Pioletti et al., 2000; Shanbhag et al., 1998; Glant and Jacobs 1994) or can 
alter osteoblast functions if their size is smaller than 10 μm (Puleo et al., 1991). As a 
result, bone formation will be delayed until the particles are completely resorbed. A 
study performed on calvarial rat osteoblasts confirmed the adverse effect of small CaP 
particles (<10 μm) on bone formation (Pioletti et al., 2000). In addition to the presence 
of small CaP particles, the cement setting and transformation can have contributed to 
the observed inflammatory response. These processes involve phase transformation of 
the ceramic with an associated substantial decrease in pH (pH was approximately 5.5) 
(Habraken et al., 2006). The increased acidity around the implant can be responsible 
for the appearance of inflammatory cells. All these observations are in agreement with 
the study of Huse et al. (Huse et al., 2004), who also found an extensive inflammatory 
infiltrate into the pores of similar injectable CaP cement loaded with TGF-β1 in an onlay 
rat model.   
Conclusion
In summary, the injectable PLGA/CaP composite stimulated bone augmentation in a rat 
model. The addition of TGF-β1 to the composite significantly increased bone contact 
at 2 weeks and enhanced new bone formation at 8 weeks. For clinical application, me-
chanical properties of the injectable composite after setting have to be improved.
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Introduction 
Emdogain® was introduced in 1997 as an alternative approach for periodontal regenera-
tion based on embryonic tooth formation [1, 2]. It is an extract of porcine enamel matrix, 
termed ‘enamel matrix derivate’ (EMD) and thought to induce mesenchymal cells to 
mimic the events that occur during root development and to stimulate regeneration of 
periodontal tissues, i.e. cementum, periodontal ligament and bone. The ability of EMD to 
enhance bone formation in a nude mouse model was defined as osteopromotive [3] and 
was suggested to be due to the enhancement of the osteoinductive potential of the graft 
material by EMD. However, it was also hypothesized that (1) EMD showed osteopromo-
tive characteristics because of the presence of bone growth stimulating factors and (2) 
a threshold concentration of EMD was required to evoke an effect. Although, early im-
munoassay studies could not identify the presence of growth factors in EMD [4], later on 
nominal levels of Transforming Growth Factor - beta 1 (TGF-ß1) [5] as well as BMP-2 
and BMP-4 were detected in an osteoinductive fraction in enamel extracts [6]. 
Calcium phosphate (CaP) ceramics are extensively used as bone substitute in dentist-
ry, orthopaedics, and reconstructive surgery due to their biocompatibility and osteocon-
ductivity. Frequently, CaP ceramics are manufactured and used in the form of granules 
or prefabricated (porous) blocks, which are unfortunately difficult to apply from a clinical 
point of view, e.g. difficulty of local maintenance of the material, lack of shaping, difficult 
delivery in the bone defect. These disadvantages have been overcome by the develop-
ment of CaP cements, which can be injected in the defect site, shaped according to the 
defect dimension and set in situ. However, depending on the composition of the final 
set product, the in vivo resorption and tissue ingrowth can be slow [7]. An approach to 
overcome this limitation is the creation of a macroporous structure within the finally set 
CaP cement. Such a concept has recently been developed in our laboratory. PLGA mi-
croparticles were incorporated in the cement to induce macroporosity [8]. Additionally, 
the inclusion of degradable microparticles provided a method for sustained delivery of 
bioactive molecules, which enhanced the bone healing process [9, 10, 11]. 
In view of the above mentioned, the objective of this experiment was to investigate the 
bone regenerative properties of Emdogain®. We hypothesized that EMD incorporated 
in different concentrations into PLGA/CaP composites could enhance bone-healing due 
to the presence of osteoinductive growth factors in the EMD. To prove this hypothesis 
PLGA/CaP composite implants and EMD incorporated PLGA/CaP composite materials 
were inserted in an orthotopic (cranial) and ectopic (subcutaneous) location in rats. 
Materials and Methods
Preparation of microparticles
PLGA microspheres were prepared using a (w/o/w) double emulsion solvent evaporation 
technique. Briefly, 1.4 g of low molecular weight (LMW) PLGA was dissolved in 2 ml of 
dichloromethane (DCM) inside a 50 ml PP tube. 500 ml of ddH2O (or 8.0/11.2 % BSA in 
ddH2O) was added while vortexing vigorously for 1 min, subsequently adding 6 ml of a 
0.3% PVA solution. Vortexing was continued for another 1 min. The content of the 50 ml 
tube was transferred to a stirred 1000 ml beaker and another 394 ml of 0.3% PVA was 
added slowly. This was directly followed by adding 400 ml of a 2% isopropylic alcohol 
(IPA) solution. The suspension was stirred for 1 hr. The spheres were allowed to settle for 
15 min and the solution was decanted. The suspension left was centrifuged, and the clear 
solution at the top was decanted. 5 ml of ddH2O was added, the spheres were washed, 
centrifuged and the solution was aspirated. Finally the spheres were frozen, freeze-dried 
for 24 hr and stored under argon at -20°C.
Preparation of PLGA/CaP implants
Implants were made by adding low-molecular poly (D, L-lactic-co-glycolic acid) (PLGA) 
microspheres (Purasorb®, Purac, Gorinchem, the Netherlands) to calcium phosphate 
cement (Calcibon®, Biomet Merck, Darmstadt, Germany), so that a weight ratio 20/80 
of PLGA/CaP cement was achieved. The chemical composition of the CaP cement was 
62.5% α-TCP (alpha tri-calcium phosphate), 26.8% CaHPO4, 8.9% CaCO3 and 1.8% 
PHA (precipitated hydroxyapatite). An aqueous solution of 1 % Na2HPO4 was used as 
a liquid component with a liquid/powder ratio of 0.35 ml/g. The cement powder was 
sterilized by gamma radiation with 25 kGy (Isotron B.V., Ede, the Netherlands) and 
the cement liquid was filter-sterilized (0.2 μm filter). Firstly, CaP cement powder pro-
vided with PLGA microparticles was added to a 2 ml plastic syringe. Subsequently, 1% 
Na2HPO4 was applied to the mixture and the mixture was shaken vigorously for 30 sec 
using a Silamat® mixing apparatus (Vivadent, Schaan, Liechtenstein). After mixing, the 
cement was immediately injected into a round mould to ensure a standardized shape 
of the samples. In this way, implants in the form of discs were created with a diameter 
of 8 mm and a height of 2 mm. These discs were removed from the molds after setting 
of the cement. The average weight of the samples was 140 mg.
Adsorption of EMD on PLGA microspheres
Thirty mg Emdogain® (BIORA AB, Malmö, Sweden) was dissolved into 800 μl of 0.1% 
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acetic acid and added to 1.0 g of microspheres, after which the EMD was freeze-dried 
onto the microspheres. 
Preparation of EMD/PLGA/CaP cement implants
PLGA/CaP cement implants provided with EMD were made by adding a fraction of 
EMD adsorbed PLGA microspheres to a fraction of as-prepared PLGA microspheres 
and subsequent mixing of both fractions through CaP cement powder. By adding di-
fferent amounts of EMD adsorbed microspheres, implants with different concentrations 
of EMD were obtained, i.e. 0.25 mg/implant, 0.50 mg/implant and 0.80 mg/implant. 
For the final shaping and setting of the implants the same procedure was followed as 
described above for non-loaded cement implants. 
Surgical procedure
The loaded and unloaded composites were inserted orthotopically and ectopically in 
rats for 4 weeks.
Orthotopic implants
For the orthotopic implantation, 24 healthy skeletally mature male Wistar rats, with an 
average weight of 250 g, were used. National guidelines for the care and use of labora-
tory animals were observed. 
In total, 24 implants were inserted into the parietal cranial bone of the rats resulting in 
four different groups of rats:
1. Group A - unloaded PLGA/CaP composites (n = 6)
2. Group B - 0.25 mg EMD per implant loaded PLGA/CaP composites (n = 6) 
3. Group C - 0.50 mg EMD per implant loaded PLGA/CaP composites (n = 6) 
4. Group D - 0.80 mg EMD per implant loaded PLGA/CaP composites (n = 6) 
For the installation of the implants, full-thickness, critical-sized cranial defects with a 
diameter of 8 mm were created [12]. Therefore, anesthesia was induced with 4% Iso-
flurane and maintained with 2% Isoflurane and 0.4% N2O, 0.4% O2 by non-rebreather 
mask and monitored to ensure that an appropriate level of anesthesia was achieved 
and maintained for surgery. The animals were premedicated by an intramuscular in-
jection of Fentanyl (2.7 ml/kg) to reduce the operative pain, and a subcutaneous injec-
tion of Buprenorphine (150 μg/kg) was applied to reduce the postoperative pain. 
Before surgery, the dorsal part of the rat cranium was shaved and swabbed by iodine. 
A median sagittal incision extending from the nasofrontal area to the occipital protu-
berance was made and soft tissues were sharp dissected to visualize the cranial peri-
osteum. The periosteum was then undermined and reflected, exposing the parietal 
bones. A hollow trephine bur (ACE Dental Implant System, USA) with an outer diam-
eter of 8 mm in a dental hand piece was used to create a full-thickness defect into the 
dorsal part of the parietal bone. Although the defect included the sagittal suture, care 
was taken not to damage the dura mater or to puncture the superior sagittal sinus. 
After insertion of the various materials, the periosteum and overlying skin were closed 
in separate layers with 5-0 and 4-0 Vicryl resorbable sutures.
Ectopic implants
For the ectopic implantation, eight male Wistar rats of 100 g were used. Each rat re-
ceived four implants subcutaneously according to a randomization scheme. In total, 32 
implants were placed, as follows: 
1. Group A - unloaded PLGA/CaP composites (n = 8)
2. Group B - 0.25 mg EMD per implant loaded PLGA/CaP composites (n = 8)
3. Group C - 0.50 mg EMD per implant loaded PLGA/CaP composites (n = 8)
4. Group D - 0.80 mg EMD per implant loaded PLGA/CaP composites (n = 8)
Surgery was performed under general inhalation anesthesia with a combination of 2% 
Isoflurane, 0.4% N2O, and 0.4% O2. The composites were subcutaneously implanted 
into the back of the animals. Four small longitudinal incisions were made through the 
full thickness of the skin on both sides of the vertebral column. Lateral to the incisions, 
a subcutaneous pocket was created using blunt dissection. Subsequently, one implant 
was inserted in each pocket. Finally, the skin was closed using Agraven suture material.
Histological preparation
The animals were euthanized using an overdose of carbon dioxide.
For the orthotopic implants, the skin was dissected and the defect sites were removed 
along with the surrounding bone and soft tissues, and fixed in 10% neutral formalin for 
one week. For the orthotopic implants, the skin was dissected and the defect sites were 
removed along with the surrounding bone and soft tissues, and fixed in 10 % neutral 
formalin for one week. The specimens were left undecalcified and were embedded in 
polymethylmethacrylate (PMMA). After polymerization, sections were prepared using 
a modified diamond-blade sawing microtome technique (Leica Microsystems GmbH, 
Wetzlar, Germany). The sections were 10 μm thick and were stained with methylene 
blue and basic fuchsin. 
For the ectopic study, implants with their surrounding tissue were retrieved, fixed in 
10% neutral formalin for one week, and embedded in PMMA. Further, the same proce-
dure for sawing and staining was carried out as described above. 
The light microscopical evaluation of all samples (both from the orthotopic and ectopic 
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study) was done using an optical microscope (Leica BW, Rijswijk, the Netherlands) 
and consisted of a complete morphological description of the tissue response to the 
different implants. 
Histomorphometry
Histomorphometrical analysis was performed only for the cranial implants. Measure-
ments were done on three digitalized sections per cranial specimen to quantify bone 
ingrowth within the defect. For this purpose, a Leica Qwin Proimage analysis system 
(Leica BV, Rijswijk, the Netherlands) was used and sections were digitized at low mag-
nification (2.5x). The newly formed bone, as defined by its woven structure and loca-
tion, was marked in an interactive manner and the computer measured its length (BL) 
in mm. Another parameter to determine was the total length of the defect, i.e. the area 
(in mm) between the defect borders that has to be filled with newly formed bone (Figure 
4A). From these two data, the length of the bone ingrowth in percentage (%) was calcu-
lated. Presented results were based on the average of these measurements.
In vitro EMD release test
To determine the release of EMD out of the PLGA/CaP implants a release test was done. 
Therefore, a sample of each EMD loaded implant group was put into a 15 ml tube with 1 
ml of Milli Q and incubated in a water bath (37°C) to mimic the conditions in the rat body. 
After 1, 3, 5 hours and 1, 2, 4, 7, 14, and 28 days, 1 ml sample of Milli Q was taken from 
the tubes and replaced by 1 ml fresh Milli Q.  The sample was put into a 15 ml tube and 
freeze-dried for 1 day. Subsequently, it was dissolved in 200 μl of MilliQ. In this way, a 
5 times higher concentration of EMD was achieved, which facilitated final analysis. To 
determine the drug release per week and cumulative release, the concentration of the 
release medium was measured by HPLC (high performance liquid chromatography) 
using a RP (reversed- phase) - column (Atlantis®, Waters corp., Milford, MA, USA). A 
30/70 mixture of acetonitril/water was used with phase containing 10% 0.1 M formic 
acid. Before each analysis, samples were filtered with Acrodisk® filters.
Statistical analysis
For the statistical analysis, GraphPad InStat program (GraphPad Software, San Di-
ego, CA.) was used. One-way Analysis of Variance (ANOVA) was performed on the 
data obtained from the histomorphometric analyses. ANOVA assumes that the data 
are sampled from populations with identical standard deviations. This assumption was 
tested using the method of Bartlett. Further, ANOVA assumes that the data are sampled 
from populations that follow Gaussian distributions. This assumption was tested using 
the method Kolmogorov and Smirnov. In addition, a Tukey-Kramer Multiple Compari-
sons Test was done. Differences were considered to be significant when p < 0.05.
Results
All animals had an uneventful recovery. Their weight remained stable and increased 
during the implantation period. Further, no infection occurred during that time. 
Descriptive histology
Cranial implants
Light microscopic examination after 4 weeks showed the presence of newly formed 
bone and no complete closure of the defects in all experimental groups. The bone 
ingrowth was initiated mainly from the dura side and defect edges, whereas no bone 
formation from the periosteal side was observed. Only a layer of connective tissue was 
present on the top of the composites that penetrated into the macropores as created by 
the degraded PLGA particles close to the surface. There was no difference in thickness 
and vascularization of this connective tissue layer between the groups. 
Newly formed bone was most abundant for unloaded implants and implants loaded with 
0.50 mg EMD. Cranial defects provided with 0.25 mg EMD loaded implants showed 
minor bone ingrowth. PLGA/CaP implants with 0.80 mg EMD induced bone formation 
comparable with the 0.25 mg EMD implants (Figure 1). 
The newly formed bone was in direct contact with the surface of both loaded and un-
loaded composites without any fibrous tissue interface (Figure 2A). Evidently, bone 
apposition was guided over the surface of the PLGA/CaP implants (Figure 2B). 
Figure : Light micrographs of PMMA embedded 
specimens showing bone ingrowth into cranial de-
fects  (0.6x magnification)
A)  unloaded implants
B) 0. mg EMD loaded implants
C) 0.0 mg EMD loaded implants
D) 0.80 mg EMD loaded implants
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Figure : Histological sections of PMMA embed-
ded specimens. Guided bone formation is visible 
with direct contact cement-newly formed bone 
without any sign of a fibrous tissue interface 
A) at the side of the dura: 40 x magnification
B) within a crack of an implant: 20 x magnifica-
tion  
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At higher magnification, the newly formed bone revealed thin trabeculae and large 
marrow spaces filled with fat tissue and haematopoietic cells. Newly formed bone had 
a woven structure without preferred orientation of the collagen fibers in the bone matrix 
and an abundance of osteoblasts and small blood vessels. Occasionally, some multi-
nucleated inflammatory-like cells were seen in contact with the cement, but they did not 
occur specifically for loaded or unloaded implants. 
All implants were maintained in the cranial defects during the implantation time and 
kept their shape and stability. 
PMMA samples showed complete maintenance of integrity of the undecalcified com-
posites. They revealed very limited degradation of the PLGA microparticles, especially 
in the middle of the composites. At the space left by the degraded microparticles, which 
was mainly at the dura and periosteal surface of the implants, fibrous tissue was ob-
served inside the resulting microporosity. In the center of the composites, no degrada-
tion of the PLGA at all was seen (Figure 3).
Histomorphometry
Histomorphometric measurements confirmed the subjective evaluation. Bone forma-
tion was most abundant for unloaded implants (54 % ± 15.0 bone ingrowth) and low-
est for the 0.25 mg EMD implants (19 % ± 22.5 bone ingrowth). For the 0.50 mg EMD 
implants, the bone ingrowth was 40 % ± 23.6, whereas for the 0.80 mg implants, it 
was 26 % ± 17.6. Statistical testing showed no significant differences (p > 0.05) in the 
amount of the newly formed bone among the EMD groups. There was a statistically 
significant difference (p < 0.05) only between the unloaded implants and those loaded 
with 0.25 mg EMD in favour of the unloaded implants (Figure 4B). 
Ectopic implantation  
Light microscopic analysis of the subcutaneous sections revealed no bone formation in 
all groups after an implantation period of 4 weeks. Only a layer of highly vascularized 
loose connective tissue was present around the composites, which penetrated into the 
macropores of the PLGA particles most close to the implant surface (Figure 5). There 
was no apparent difference in the thickness of this fibrous capsule or in vascularization 
among the various implant groups. Occasionally, some multinucleated inflammatory-
like cells were observed at the surface of all implant groups. 
All implants maintained their integrity and shape during implantation and only limited 
degradation of the PLGA particles was observed, as characterized by the absence of 
tissue structures in the macroporosity.
In vitro EMD release study
The results of the in vitro EMD kinetics are depicted in Figure 6. An initial burst release 
of about 10% of the total dose of EMD was observed during the 1, 3 and 5 hours for all 
EMD loaded implant groups. Subsequently, a sustained release profile was observed 
during the 1st week of incubation. Thereafter, the release increased rapidly (Fig 6A) and 
was calculated to be about 35% per week. At day twenty-eight, 60% of the total amount 
of EMD loaded in the PLGA/CaP implants was released in the medium (Fig 6B).
Figure : Results of the in vitro EMD release study
A) Release of EMD per week
B) Total (cumulative) release of EMD
Figure : Light micrograph showing the presence of non-degraded PLGA 
microparticles in the centre of the composites (20 x magnification). 
Figure  
A) Histomorphometric measurements of the bone length ingrowth: total length of the defect marked in green; 
length of the newly formed bone marked in blue
B) Histomorphometric measurements of bone length ingrowth in percentage for all groups
Figure : Fibrous tissue capsule around the subcu-
taneous implants-PMMA samples, basic fuchsine 
0.6 x magnification
A)  unloaded implants
B) 0. mg EMD loaded implants
C) 0.0 mg EMD loaded implants
D) 0.80 mg EMD loaded implants
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Discussion
The present study failed to support the hypothesis that EMD can enhance bone re-
generation when applied in combination with an osteoconductive material orthotopi-
cally and induces bone formation ectopically. On the contrary, less bone formation was 
observed compared with the PLGA/CaP composites alone in the critical-sized cranial 
defects. Nevertheless, 0.50 mg EMD loaded implants tended to result in more bone 
ingrowth than 0.25 mg and 0.80 mg EMD loaded implants. This finding is in agreement 
with the in vitro study of Yoneda et al. 2003 [13], in which the effect of EMD on osteo-
blastic cells was evaluated. They demonstrated that EMD affected the cell proliferation, 
ALP activity and mineralized nodule formation in a concentration-dependent manner, 
whereas the most favorable concentration of EMD was reported to be 0.50 mg. On the 
other hand, in the in vivo part of the same study, in which EMD-loaded collagen pellets 
were inserted into 3.8 mm full thickness cranial defects for an implantation period of 2 
weeks, the released EMD stimulated new bone formation, which does not corroborate 
our observations. This discrepancy can be due to the fact that in the in vivo experiment 
of Yoneda et al. smaller defects (3.8 mm in diameter versus 8 mm), shorter implantation 
periods (2 weeks versus 4 weeks), and a higher concentration of EMD (1 mg versus 
0.25 mg, 0.50 mg, 0.80 mg) were used, which might have resulted in better outcomes. 
Moreover, a different delivery vehicle (collagen pellet versus PLGA/CaP cement) was 
used, and although the EMD release profile was not reported, it might also have af-
fected the study results. Further, it has to be noticed that Yoneda et al. included an 
empty defect as control group, whereas we used PLGA/CaP implants as control, which 
have already demonstrated excellent osteogenic capacity. 
In our study 0.80 mg EMD loaded composites caused less bone ingrowth than the 0.50 
mg EMD loaded (40% bone formation versus 27%). An explanation can be that there is 
an optimal dose of action of EMD, which when being exceeded or not reached results 
in an inhibitory effect. This was already observed in an in vitro study with EMD and PDL 
cells [14]. In this study, the viability of PDL cells was observed negatively affected by 
higher doses of EMD over time, while lower doses elicited no change when compared 
with control cultures.
The conclusion of the present study that EMD does not provide an additional stimulus 
for bone formation is supported by the findings of Donos et al. [15, 16]. In one of their 
studies, cranial defects with a diameter of 5 mm were treated with barrier membranes 
and/or EMD, and demineralised bovine bone matrix (DBBM) plus EMD versus a com-
bination of a barrier, EMD and DBBM for 4 months. The combined use of the barriers 
with EMD did not significantly enhance bone healing. Therefore, the authors even sug-
gested that the use of EMD for the purpose of generating new bone in clinical situations 
should be questioned. The same is true for the possible osteoinductive nature of EMD. 
Previous studies of Boyan et al. [3] and Yoneda et al. [13], suggested already that EMD 
does not have bone morphogenetic protein (BMP)–like osteoinductive activity. Our in-
vestigation confirmed this observation, since no bone formation was found when EMD 
composites were implanted subcutaneously for 4 weeks. 
Delivery systems are of great importance when growth factors are used to enhance 
wound healing [17, 18]. Considering our histological findings, i.e. the lack of a bone 
formation enhancing effect of the EMD-loaded PLGA/CaP implants, it can be assumed 
that the present delivery system of EMD was not appropriate.  In view of this, an in vitro 
release study was done to obtain information about the release kinetics of EMD. Our 
findings correspond to the release profiles of other growth factors from the same CaP 
cement [9, 10]. In our study, the initial burst release of 10% was due to the release of 
EMD from the surface of the scaffold. Afterwards, the release was sustained until day 7, 
when low molecular PLGA particles started to erode. At day 14, the erosion of the PLGA 
particles was complete, which resulted in fast increase in the EMD release profile. After 
four weeks, 60% of the total amount of EMD present in the PLGA/CaP composites was 
released in the medium and it seemed that this increasing pattern continued. However, 
in vivo release patterns are known to differ from the in vitro situation with a lower re-
lease profile in vivo compared with in vitro [9, 10]. Besides that, CaP cement has been 
reported to exhibit a high protein binding affinity [19]. As a consequence, interaction of 
EMD with CaP cement can have occurred, which can have hampered additionally the 
final release of EMD. Therefore, it cannot be excluded that the released EMD failed to 
reach the dose required to evoke an effect. However, further investigations with other 
carrier materials or higher concentrations of EMD, as well as in vivo release assays of 
EMD are required to prove this hypothesis.  
The current results confirmed again the excellent biocompatibility and osteoconductiv-
ity of PLGA/CaP cement [20, 21]. Although, the material was applied in a preset condi-
tion, defects with unloaded PLGA/CaP composites showed the most abundant bone 
formation. In all cranial specimens, a direct contact between the newly formed bone 
and the composites was found, whereas a few multinucleated inflammatory cells were 
seen on the cement surface. 
Conclusion
In summary, we conclude that in the current study Emdogain® was found to lack 
osteoinductive properties and was not able to enhance bone healing in combination 
with an osteoconductive PLGA/CaP material. However, the limited release pattern of 
EMD for the period of 4 weeks should be taken into account. Therefore, as the exact 
action mechanism of EMD is still unknown, further investigations are required. 
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1. Concluding remarks
During the last decades, the improved understanding of wound healing and tissue re-
generation processes together with the scientific discoveries in cellular and molecular 
biology have led to the development of novel multidisciplinary fields like regenerative 
medicine and tissue engineering. Regenerative medicine and tissue engineering em-
ploy biomimicry, since they seek to mimic the body’s natural tissue formation processes 
to form functional living tissue. As a consequence, the concept of “biological solutions 
to biological problems” has emerged as a new paradigm in contemporary dentistry and 
medicine (Slavkin & Bartold 2006). For example, as a consequence of the development 
of biologically active additives, such as growth factors, platelet-rich plasma and enamel 
matrix derivates are currently used in clinical procedures for bone regeneration. While 
in their majority these biologically active additives offer improvement in clinical results, 
better understanding of their exact mechanism of action is still needed. In view of this, 
the main research outcomes of the chapters of this thesis are discussed below.
PRP
The use of PRP is a relatively new approach, which clinical efficiency is supposed to be 
due to the local and continuous delivery of a wide range of GFs and proteins (adhesive 
molecules), mimicing the needs of the physiological wound healing and reparative tis-
sue processes. Recently, upon its development PRP has been directly introduced into 
the clinic as an enhancer for bone regeneration (Marx et al. 1998), which caused a big 
discussion among the researchers about the biology of PRP, its mode of action and re-
levance for clinical application (Schmitz & Hollinger 2001, Freymiller & Aghaloo 2004). 
Nevertheless, since then, PRP has been widely used in the dental practice for treat-
ment of periodontal defects, sinus lift procedures, oral-maxillofacial reconstructions, 
alveolar ridge augmentations, implant placement and treatment of extraction sockets. 
Overall, in the dental literature the reported effects of PRP on bone healing in humans 
are contradictory. Our systematic review (Chapter 2), undertaken to address this issue, 
found evidence only for the use of PRP in treatment of periodontal defects. Current 
evidence for the beneficial effect of PRP on bone regeneration in sinus elevation pro-
cedures was considered weak. Furthermore, this systematic review revealed a serious 
lack of good quality clinical trials, which made it impossible to draw solid conclusions 
on the relevance of other PRP applications.
In an attempt to give some more insight into the mode of action of PRP, its early and 
late effects on bone healing were studied in a rat model (Chapter 3 and Chapter 4). 
Syngenetic animals were chosen for these experiments to meet the main requirement 
of PRP as an autologous product. Further, rat PRP as prepared had a 3-fold increase 
of platelets above their base-line number in the whole rat blood, which is in correspon-
dence with the concentration of platelets obtained by one of the FDA approved devices 
(3i PCCS) (Marx 2004). Our results showed that at both early and late time points PRP 
failed to enhance bone regeneration in combination with an osteoconductive material. 
In addition, no difference between PRP liquid and PRP gel on bone formation was 
observed, except for the beneficial effect of the gel on the ease of handling of the graft. 
To elucidate further the bone regenerative effect of PRP and to provide an explanation 
for the discrepancy in the literature about its impact on bone healing, it was decided to 
examine and compare some of the most studied experimental PRP formulations (rat, 
goat and human) (Chapter 5). Our findings showed that rat and goat PRP had no effect 
on bone formation neither at early nor at late time points in the used immunodeficient 
rat model. In contrast, human PRP was able to enhance the initial osteogenic capacity 
of human bone graft material, and its addition to an autogenous bone graft appeared 
to be more beneficial than to a synthetic bone substitute. These findings corroborate 
the hypothesis of the mode of action of PRP and confirmed the results of our previous 
studies. 
TGF-β1
The importance of TGF-β1 in bone development and homeostasis has been exten-
sively demonstrated both in vitro and in vivo with strong evidence for profound effects 
on bone formation, bone resoption, and the interplay between these two processes. 
However, results obtained from different studies are often not in line with and even 
contradictory to each other. In this research (Chapter 6), the bone regenerative effect 
of TGF-β1 in combination with an osteoconductive material was examined. TGF-β1 ap-
plied in a low concentration was able to increase the intial bone contact and to enhance 
bone augmentation at later time points. Several questions arose from our findings. It 
remained unclear why TGF-β1 failed to stimulate the early amount of bone formation, 
but at the same time increased the initial bone contact. Additional research is required 
to elucidate the observed effects of TGF-β1.
EMD
In 1997 Hammarström introduced an alternative approach for periodontal regenera-
tion based on biomimicry (Hammarstrom 1997). This approach uses EMD to mimic 
the events that occur during root development and thereby to stimulate periodontal 
regeneration. Results from in vitro and in vivo studies have shown that EMD is able to 
induce regeneration of cementum, periodontal ligament and alveolar bone. However, 
the specific characteristic of EMD regarding just bone formation is still ambiguous. In 
this research (Chapter 7), the bone regenerative properties of EMD were investigated 
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in combination with an osteoconductive material. Our findings revealed that EMD was 
neither osteoinductive, nor able to enhance bone healing. The lack of osteoinductivity 
of EMD has already been reported, but in the majority of the studies, a stimulatory ef-
fect of EMD on bone growth has been demonstrated. Therefore, the outcomes of our 
study must be interpreted within the limitations of the study model. Further studies with 
other carrier materials and higher concentrations of EMD are necessary to corroborate 
these results. 
 2. Future perspectives
With an increasing number of older people and an increasing life expectancy worldwide, 
there is an increasing clinical need for effective and minimal invasive bone regeneration 
treatment options. The “holy grail” of bone regeneration is the development of “smart” 
materials that do not require additional biologically active factors. These materials are 
alleged to exactly mimic the natural bone environment, serving as a scaffold for the 
orchestrated activation of local cellular processes. 
PRP has appeared as a promising innovation for stimulation and acceleration of the 
bone healing process. However, the exact mechanisms by which PRP enhances initial 
bone healing has still to be fully understood. Therefore, suitable animal models/prepa-
rations are necessary to elucidate the effects of PRP. One of the aspects for future 
research must be the standardization of the animal PRP preparations and their com-
plete adjustment to the human PRP in view of procurement technique, concentration 
of platelets and increase above the platelets base number achieved, level of GFs, 
acce-lerators. In this respect goat PRP appears to be a suitable model, due to the 
comparable number of platelets between the human and goat blood. However, further 
research is required for example to elucidate the discrepancy in the data about the 
exact number of platelets in the goat blood.
In addition, the combination of PRP with different kind of synthetic bone substitutes 
must be further explored. Significant advance in the promotion of bone healing may be 
expected by the development of an appropriate scaffold for PRP, which on one hand, 
approximates the natural extracellular matrix and on the other, allows delivery of the 
GFs stored in PRP in a specific spatial and temporal sequence. This may not only 
enhance bone formation, but also enable engineering of large volumes of functional 
bone tissue in the future. Finally, well-designed controlled clinical trials are necessary 
to demonstrate the bone regenerative effect of PRP and to provide solid evidence for 
its clinical application.
With regards to TGF-β1, future research is required to reveal which is the optimal dose 
of TGF-β1 to enhance bone healing and which is its optimal carrier for treatment of 
large bone defects, so that it can reach clinical application.
In view of EMD, it appears reasonable to assume that the matrix-cell principle of Em-
dogain® can also be applied in other clinical situations, besides treatment of periodontal 
defects. The use of an insoluble matrix that intiates a series of cellular events may be 
especially favorable, since cells involved will then provide the GFs and tissue compo-
nents necessary for regeneration. 
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The present research is focused on the application of different biologically active addi-
tives for bone tissue regeneration. The aim was to acquire more information about the 
efficacy of their bone regenerative properties and relevance for clinical application.
In Chapter  a brief overview of different approaches for bone tissue regeneration is 
presented, while the emphasis is placed upon biologically active additives currently 
used for this purpose.
The aim of Chapter  was to summarize data available in the literature and to provide 
evidence for clinical application of platelet rich plasma (PRP) in oral maxillo-facial bone 
regeneration. For this purpose, up to June 2006, MEDLINE and Cochrane databases 
were explored with different combinations of three search terms: “PRP”, “bone regen-
eration”, “dentistry” and their synonyms. Inclusion criteria were: human controlled clini-
cal trials designed to treat maxillo-facial bony defects with application of PRP (test) or 
without PRP (control), including at least 5 patients with a follow-up period more than 3 
months and using clinical assessment, radiography, histology and /or histomorphom-
etry as evaluation. Literature search, selection of eligible articles, and data extraction 
were carried out independently by two readers. The literature search revealed 108 
references, of which 17 were selected for further analysis. Finally, 9 articles fulfilling the 
inclusion criteria, were selected to review systematically. Due to the substantial hetero-
geneity of the studies it was not possible to statistically analyse the data. An attempt 
was made to compare results from studies that used similar outcome measures by cal-
culating and adding Confidence Intervals to the data presented in the original papers. 
Differences in treatment effects for periodontal defects in terms of clinical attachment 
level (CAL) were significant (ranging from 0.8 to 3.2 mm). The reported effects of PRP 
in sinus elevation (compared to their controls) were less than 10%. It was concluded 
that evidence existed for beneficial effects of PRP in treatment of periodontal defects. 
Evidence for beneficial effects of PRP in sinus elevation appeared to be weak. No con-
clusions can be drawn about other applications of PRP in dentistry.
Chapter  deals with the early effect of PRP on bone regeneration. The early effect of 
PRP was evaluated in addition to dense biphasic ceramic particles hydroxyapatite-β-
tricalciumhosphate (HA/ß-TCP) with ratio 60/40 in rat cranial defects with a diameter 
of 6.2 mm. The defects were filled with HA/ß-TCP particles and HA/ß-TCP particles 
combined with PRP gel, but also some were left unfilled as a control. One and two 
weeks after surgery specimens were retrieved for light microscopy (hematoxylin-eosin, 
trichrome staining and basic fuchsin-methylene blue) and μCT analysis to evaluate 
bone formation and neovascularisation. One-way Analysis of Variance (ANOVA) was 
performed on the raw data obtained from μCT analysis. Light microscopic evaluation 
showed no effect of PRP on bone formation, neither during the first week, nor during 
the second week. Further, no effect of PRP on neovascularisation was observed, since 
no difference in the number of the new blood vessels was subjectively detected in 
the trichrome stained samples. On the other hand, the trichrome staining indicated an 
increase in bone maturity after two weeks in both groups with particles. In view of the 
dense HA/ß-TCP particles (60/40), hematoxylin-eosin and methylene blue/basic fuch-
sin stained slides revealed their osteoconductive nature. The quantitative μCT analysis 
demonstrated a statistically significant difference in new bone formation between the 
empty defects and the defects filled with particles after one week of implantation, but 
there was no difference between the non-PRP and PRP groups. At the second week 
no difference among all groups was observed, while even the non-filled control defects 
were almost completely closed. It was concluded that rat PRP had no effect on the ear-
ly stages of bone healing in addition to an osteoconductive material. Dense HA/ß-TCP 
particles with size 300-500 μm and ratio 60/40 showed a beneficial effect on bone 
formation during the first and second week in non-critical-sized cranial defects in 
rats. A 6.2 mm cranial defect turned out not to be a critical-sized defect in rats.
Chapter  deals with the late effect of platelet-rich plasma on bone regeneration. Crani-
al defects, 6.2 mm in diameter, were filled with HA/ß-TCP particles, HA/ß-TCP particles 
combined with PRP and HA/ß-TCP particles combined with PRP gel, where some were 
left empty as a control. After four weeks of implantation histological, histomorphometri-
cal and μCT analyses revealed no difference in new bone formation among the groups. 
Further, no additional effect of PRP gel in comparison to PRP liquid was detected, 
except for the increased handling capacity of the graft. These findings suggested that 
PRP had no positive effect on bone formation in addition to an osteoconductive mate-
rial after an implantation period of four weeks. On the other hand, also no negative ef-
fect was seen, neither PRP nor HA/ß-TCP hampered bone ingrowth into the defects.
The aim of Chapter  was to examine and compare the bone regenerative effect of 
PRPs of different species (rat, goat, human). In addition, osteogenic capacity of hu-
man bone graft (HB) vs. HB combined with human PRP (HB+hPRP) and HB+hPRP 
vs. synthetic hydroxyapatite-tricalcium phosphate bone substitute combined with 
hPRP (HA/TCP+hPRP) was studied. For this purpose, 72 implants, divided in six 
groups (n = 6) were inserted in critical-sized cranial defects (8 mm) of immunode-
ficient rats. After two and four weeks, descriptive and quantitative histological, and 
μCT analyses were performed on the retrieved specimens. Results showed that rat 
and goat PRP combined with HA/TCP did not enhance bone regeneration compared 
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to HA/TCP. In contrast, human PRP combined with HA/TCP resulted in significantly 
increased bone fill compared to HA/TCP alone. Similarly, the addition of human PRP 
to human bone graft increased significantly the amount of newly formed bone after 
two weeks. Evidently, HB+hPRP demonstrated enhanced bone healing compared to 
HA/TCP+hPRP. It was concluded that rat and goat PRP had no effect on bone for-
mation. Human PRP improved the initial osteogenic response of human bone graft. 
Human PRP combined with human bone graft had better osteogenic capacity than 
human PRP combined with synthetic bone substitute. 
Chapter  deals with the bone augmentation properties of Transforming Growth Factor 
β1 (TGF-ß1; 200 ng) incorporated in an injectable polylactic-glycolic acid/calciumphos-
phate PLGA/CaP (20/80) composite. For this purpose, PLGA/CaP composites (control) 
and PLGA/CaP composites loaded with TGF-β1 (test group) were injected on top of the 
skulls of 24 Wistar rats. Each rat received two materials from the same experimental 
group, and in total 48 implants were placed (n = 8). After two, four, and eight weeks 
the results were evaluated histologically and histomorphometrically. The contact length 
between the implants and newly formed bone increased in time, and it was significantly 
higher for the TGF-β1 composites after two weeks. Also, bone formation was signifi-
cantly higher for the TGF-β1 composites (18.5% ± 3) compared to controls (7.21% ± 
5) after eight weeks of implantation. The immunohistochemical staining demonstrated 
massive inflammatory infiltrate in both groups, particularly at two weeks, which de-
creased substantially at four and eight weeks. It was concluded that the injectable 
PLGA/CaP composite stimulated bone augmentation in a rat model. The addition of 
TGF-β1 to the composite significantly increased bone contact at two weeks and en-
hanced new bone formation at eight weeks.
The aim of Chapter  was to evaluate the bone regenerative properties of Emdogain® 
(EMD) in osseous and non-osseous sites. For the orthotopic study, unloaded PLGA/CaP 
implants, and PLGA/CaP implants loaded with different concentrations of EMD: 0.25, 
0.50 and 0.80 mg/implant were inserted into cranial defects of 24 rats. The implantation 
time was four weeks. For the ectopic study, 32 implants were placed subcutaneously. 
The same study period and groups as in the orthotopic study were used. Methods of 
evaluation consisted of descriptive histology, histomorphometry, and an in vitro EMD 
release study. In the orthotopic study, new bone formation was most abundant in unload-
ed implants followed by 0.50 mg EMD composites. Histomorphometric measurements 
showed 54 % ± 15.0  bone ingrowth for unloaded, 19 % ± 22.5 for 0.25 mg, 40 % ± 23.6 
for 0.50 mg and 26 % ± 17.6 for 0.80 mg EMD composites. Light microscopic analysis 
of the subcutaneous sections from the ectopic study revealed no bone formation in all 
groups after four weeks.
The in vitro release study showed 60% cumulative EMD release after four weeks. It 
was concluded that Emdogain® was not osteoinductive, and was not able to enhance 
bone healing in combination with an osteoconductive material, such as PLGA/CaP 
cement.
The most important findings of this thesis are discussed in Chapter 8 and directions for 
future studies are given. 
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Chapter 10
Samenvatting en evaluatie van de doelstellingen
0 
Het onderzoek beschreven in dit proefschrift is gericht op de toepassing van verschil-
lende biologisch actieve toevoegingen voor botregeneratie. Het doel was meer infor-
matie te verkrijgen over de werkzaamheid, de botregeneratieve eigenschappen en de 
relevantie voor klinische toepassing van deze toevoegingen.
In hoofdstuk  wordt een overzicht gegeven van verschillende aanpakken om botre-
generatie te bewerkstelligen. In dit overzicht ligt de nadruk op biologisch actieve to-
evoegingen, welke momenteel gebruikt worden voor dit doel.
Het doel van hoofdstuk  was het samenvatten van beschikbare gegevens uit de liter-
atuur en daarmee bewijs leveren voor het nut van klinische toepassing van platelet-rich 
plasma (PRP) ten behoeve van botregeneratie in het orale en maxillofaciale gebied. 
Daartoe werden databases van MEDLINE en Cochrane geraadpleegd (tijdspanne tot 
juni 2006) middels verschillende combinaties van drie zoektermen: ‘PRP’, ‘bone re-
generation’ en ‘dentistry’ (en hun synoniemen). De ‘hits’ uit de literatuurraadpleging 
dienden te voldoen aan de volgende criteria: humane klinische studies gericht op de 
behandeling van maxillofaciale botdefecten, waarbij gebruik gemaakt wordt van PRP 
(test) of niet (controle), met minimaal 5 patiënten en een follow-up van minimaal 3 
maanden, gebruikmakend van de volgende evaluatietechnieken: klinische beoordel-
ing, radiografie, histologie en/of histomorfometrie. De literatuurraadpleging, selectie 
van geschikte wetenschappelijke artikelen en data extractie werd onafhankelijk uit-
gevoerd door 2 personen. De literatuurraadpleging leverde 108 ‘hits’ op, waarvan er 
initieel 17 werden geselecteerd. Na controle op vereiste criteria, werden uiteindelijk 
9 wetenschappelijke artikelen geselecteerd voor een systematische review. Gezien 
de grote verschillen in opzet van de studies was het onmogelijk de data statistisch 
te analyseren. Derhalve werd getracht de resultaten te vergelijken van studies, waa-
rin dezelfde parameters gebruikt werden middels het berekenen en toevoegen van 
betrouwbaarheidsintervallen aan de hand van de originele data van de studies. Sig-
nificante verschillen werden gevonden voor behandelingseffecten voor parodontale 
defecten, meer specifiek voor clinical attachment level (CAL; range 0.8 – 3.2 mm). 
De beschreven effecten van PRP voor sinus elevatie (vergeleken met de controles) 
waren minder dan 10%. De conclusie van de systematische review was dat bewijs 
was geleverd voor positieve effecten van PRP voor de behandeling van parodontale 
defecten. Voor positieve effecten van PRP voor sinus elevatie was het bewijs slechts 
zwak. Verdere conclusies over het gebruik van PRP voor andere toepassingen in de 
tandheelkunde konden niet worden getrokken.
Hoofdstuk  beschrijft de vroege effecten van PRP op botregeneratie. Deze vroege effec-
ten werden onderzocht door PRP wel of niet toe te voegen aan bi-fasische keramische 
partikels (hydroxyapatiet/β-tricalciumfosfaat; HA/β-TCP in de verhouding 60/40) in een 
diermodel met craniale defecten in ratten met een diameter van 6.2 mm. De gemaakte 
defecten werden gevuld met enkel HA/β-TCP of met de combinatie van HA/β-TCP met 
PRP gel. Daarnaast werden enkele defecten onbehandeld gelaten ter controle. Op 
een en twee weken na operatie werden de defecten (inclusief omliggend weefsel) her-
nomen voor evaluatie middels lichtmicroscopie (histologische kleuringen: hematoxylin-
eosin, trichrome en basische fuchsine-methyleen blauw) en micro-CT op botformatie 
en neovascularisatie. Een variantie-analyse (ANOVA) werd uitgevoerd op de ruwe data 
van de micro-CT analyse. Lichtmicroscopisch werd geen effect waargenomen van PRP 
op botformatie voor beide implantatie-periodes. Daarnaast werden ook geen effecten 
van PRP op neovascularisatie waargenomen, aangezien geen verschillen in aantal-
len nieuwe bloedvaten werden gezien tussen de verschillende experimentele groepen 
(histologische, trichrome-gekleurde coupes). Echter, trichrome-gekleurde coupes ver-
toonden wel een verhoogde botweefsel maturatie na twee weken in beide groepen met 
keramische partikels. Zowel hematoxylin-eosin als basische fuchsine/methylene blauw 
kleuring van de histologische coupes liet duidelijk de osteoconductieve eigenschap-
pen van de keramische partikels zien. De kwantitatieve micro-CT analyse leverde een 
statistisch significant verschil op v.w.b. de formatie van nieuw botweefsel op één week 
tussen lege defecten en defecten gevuld met keramische partikels, waarbij opgemerkt 
dient te worden dat de toevoeging van PRP geen verschil maakte. Na een implantatie-
periode van twee weken werd geen significant verschil gevonden tussen de verschil-
lende groepen en zelfs de lege defecten waren bijna geheel geregenereerd. De conclu-
sie van deze studie was dat PRP geen additioneel effect heeft op de initiële genezing 
van botweefsel boven het gebruik een osteoconductief materiaal. Keramische partikels 
met een grootte van 300-500 µm hebben een positief effect op botformatie tijdens de 
eerste twee weken in een non-critical-sized craniaal defect in ratten. Een craniaal de-
fect in ratten met een diameter van 6.2 mm is een non-critical-sized defect.
Hoofdstuk  beschrijft onderzoek naar de late effecten van PRP op botregeneratie. 
Craniale defecten (Ø 6.2 mm) in ratten werden gevuld met HA/β-TCP partikels, al dan 
niet gecombineerd met PRP of PRP gel. Daarnaast werden enkele defecten onbe-
handeld gelaten ter controle. Na een implantatieperiode van vier weken werden geen 
verschillen gezien in botformatie tussen de verschillende groepen, gebruikmakend van 
evaluatie middels histologie, histomorfometrie en micro-CT analyse. Daarnaast bleek 
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er geen effect te zijn van de vorm waarin PRP werd gebruikt (vloeistof of gel), behalve 
in het licht van de verwerking van het materiaal. Deze vindingen suggereren derhalve 
dat PRP geen positief effect heeft op botregeneratie in combinatie met een osteo-
conductief materiaal na een implantatieperiode van vier weken. Opgemerkt dient te 
worden dat de toepassing van PRP in combinatie met HA/β-TCP ook geen negatieve 
effecten tot resultaat had.
Het doel van hoofdstuk  was vergelijkend onderzoek te doen naar de botregeneratieve 
effecten van PRP’s van verschillende species (rat, geit en humaan). Daarnaast werd 
gekeken naar de osteogene capaciteit van humaan bot en de combinatie ervan met hu-
maan PRP (hPRP), alsook die van synthetisch keramiek (HA/β-TCP) en de combinatie 
ervan met hPRP. Daartoe werden 72 implantaten, verdeeld over zes groepen (n = 6), ge-
plaatst in een critical-sized craniaal defect (Ø 8 mm) in immunodeficiente ratten. Na twee 
en vier weken werd beschrijvende en kwantitatieve histologische en micro-CT analyse 
uitgevoerd. De resultaten toonden dat PRP van rat en geit in combinatie met synthetisch 
keramiek de botregeneratie niet bevorderen t.o.v. enkel synthetisch keramiek. Echter, 
de combinatie van hPRP met synthetisch keramiek resulteerde wel in een significante 
verhoging van gevormd botweefsel in vergelijking met enkel synthetisch keramiek. In par-
allel hiermee vertoonde ook de combinatie hPRP met humaan bot een significante ver-
hoging nieuw gevormd botweefsel na twee weken. Bovendien was de botvorming hoger 
voor hPRP gecombineerd met humaan bot dan met synthetisch keramiek. Concluderend 
toonde deze studie dat PRP van rat en geit origine geen effect heeft op botvorming. Hu-
maan PRP bezit wel de capaciteit om de initiële botrespons in combinatie met humaan 
bot te verbeteren. Verder heeft de combinatie van hPRP met humaan bot een betere 
osteogene capaciteit dan die met synthetisch keramiek.
Hoofdstuk  beschrijft de botvermeerderings-eigenschappen van transforming growth 
factor β1 (TGF-β1; 200 ng), geïncorporeerd in een injecteerbaar poly(lactic-glycolic) 
acid/calciumfosfaat (PLGA/CaP; 20/80) composiet. Ongeladen controle composiet en 
TGF-β1 geladen composiet werd geïnjecteerd bovenop de schedel van 24 Wistar rat-
ten. Bij iedere rat werden twee composieten van dezelfde experimentele groep ge-
plaatst, waardoor in totaal 48 implantaten (n = 8) werden gebruikt. Histologische en 
histomorfometrische evaluatie vond plaats na implantatieperiodes van twee, vier en 
acht weken. De contactlengte tussen composiet en nieuw gevormd botweefsel nam 
toe met de tijd, waarbij deze lengte significant hoger was voor TGF-β1 geladen com-
posiet na twee weken. Bovendien was ook de botvorming hoger voor TGF-β1 geladen 
composiet (18.5% ± 3) t.o.v. ongeladen controle composiet (7.2% ± 5) na acht weken. 
Immunohistochemische kleuringen toonden een ontstekingsinfiltraat in beide groepen 
vooral na twee weken, waarna de ontstekingsreactie verminderde met de tijd. De con-
clusie van deze studie was dat injecteerbaar PLGA/CaP composiet botvermeerdering 
stimuleert in een ratten model. De toevoeging van TGF-β1 zorgt voor een significante 
verhoging van botcontact op twee weken en botformatie op acht weken.
Het doel van hoofdstuk  was de botregeneratieve eigenschappen van Emdogain® te 
evalueren, zowel binnen (orthotopisch) als buiten (ectopisch) een botomgeving. Voor 
de orthotopische evaluatie werden ongeladen en Emdogain®-geladen (0.25, 0.50 en 
0.80 mg/implantaat) PLGA/CaP implantaten geplaatst in craniale defecten in 24 rat-
ten voor een periode van vier weken. Ectopisch werden 32 implantaten subcutaan 
geplaatst voor een periode van vier weken. De evaluatie bestond uit beschrijvende 
histologie, histomorphometrie en een in vitro Emdogain® release experiment. In een 
orthotopische omgeving vertoonden ongeladen implantaten de meeste botvorming, 
gevolgd door 0.50 mg Emdogain®-geladen implantaten. Histomorfometrie toonde een 
botingroei van 54 ± 15.0%, 19 ± 22.5%, 40 ± 23.6% en 26 ± 17.6% voor respectievelijk 
ongeladen en 0.25, 0.50 en 0.80 mg Emdogain®-geladen implantaten. In geen enkele 
van de ectopische implantaten werd lichtmicroscopisch botformatie aangetroffen. De 
in vitro release studie liet een cumulatieve Emdogain® release van 60% zien in vier 
weken. De conclusie van deze studie was dat Emdogain® niet osteoinductief is en niet 
in staat is om de botgenezing te verbeteren in combinatie met een osteoconductief 
materiaal als PLGA/CaP.
De belangrijkste vindingen van het onderzoek beschreven in dit proefschrift worden be-
discussieerd in hoofdstuk 8, waarin tevens wordt aangegeven welk toekomstig onder-
zoek belangrijk is op dit gebied.
Chapter 0 Samenvatting en evaluatie van de doelstellingen
10 10
 
Publicaties gerelateerd aan dit proefschrift:
. Plachokova AS, van den Dolder J, Stoelinga PJ, Jansen JA. The bone regenerative 
effect of platelet-rich plasma in combination with an osteoconductive material in rat 
cranial defects. Clin Oral Implants Res. 00, :0-. 
. Plachokova AS, van den Dolder J, Stoelinga PJ, Jansen JA. Early effect of platelet-
rich plasma on bone healing in combination with an osteoconductive material in rat 
cranial defects. Clin Oral Implants Res. 00;8: -.
. Plachokova AS, Link D, van den Dolder J, van den Beucken JJP, Jansen JA. Bone 
regenerative properties of injectable PLGA-CaP composite with TGF-ß in a rat aug-
mentation model. J Tissue Eng Regen Med. 00, : -. 
. Plachokova AS, van den Dolder J,  Jansen JA. The bone-regenerative properties of 
Emdogain® adsorbed onto poly(d,l-lactic-coglycolic acid)/calcium phosphate compos-
ites in an ectopic and an orthotopic rat model. J Periodont Res. 008, : -.
. Plachokova AS, Nikolidakis D, Mulder J, Jansen JA, Creugers NHJ. Effect of platelet-
rich plasma on bone regeneration in dentistry-a systematic review. Clin Oral Implants 
Res. 008, 9: 9-.
. Plachokova AS, van den Dolder J, van den Beucken JJP, Jansen JA. Bone regenera-
tive properties of rat, goat and human PRP. Bone; submitted
Presentaties:
. Plachokova AS, van den Dolder J, Stoelinga PJ, Jansen JA.The bone regen-
erative effect of platelet-rich plasma in combination with an osteoconductive mate-
rial in rat cranial defects, 8th Annual Tissue Engineering Society International (TESI) 
Conference&Exposition (October -, 00), Shanghai, China
. Plachokova AS, van den Dolder J, Jansen JA.The Bone Regenerative Properties 
of Emdogain®, IADR/AADR/CADR 8th General Session and Exhibition (March -, 
2007), New Orleans, USA- finalist for Young Investigator’s Award in the Implantology 
Research Group
. Nikolidakis D, Plachokova AS, Jansen JA, Creugers NHJ. Effect of PRP on Alveolar 
Bone Regeneration: a Systematic Review, nd Annual meeting of IADR-Continental 
European and Israeli Divisions (Sept -9, 00), Thessaloniki, Greece
. Plachokova AS, van den Dolder J, van den Beucken JJP, Jansen JA. Bone regen-
erative properties of platelet-rich plasma, IADR/AADR/CADR 8th General Session and 
Exhibition (July -, 008) Toronto, Canada 
                                                                                                                              
Chapter 11
Acknowledgements
Chapter 0 
10
 
I find it difficult to consider this thesis as a personal achievement, rather I look at it 
as the outcome of mutual efforts of many people who supported me unconditionally 
through all these years. I owe them a lot, and hope to have proven that it has been 
worth giving me their confidence, time and expertise. Although it is not possible to 
mention everyone by name, I would like specifically to acknowledge the following 
people.
First and foremost I would like to express my deepest gratitude to my supervisor Prof. 
dr. John Jansen. Dear John, thank you for the unique opportunity that you gave me 
to conduct research in your department and, most of all, for your confidence! It has 
been a challenge for me, an ordinary dentist by background, to try to attain the high 
scientific level that you have set in your department. Your expertise not only as a 
scientist, but also as a dentist convinced me that it is possible to be a researcher and 
a clinician at the same time. I have learned a lot from you and there is still a lot to be 
learned. Your extensive knowledge and creativity have always been my inspiration. 
I highly appreciate your perfectionism and willingness to give the best and to expect 
the same from me and the rest. I can’t stop admiring your working enthusiasm, your 
availability twenty-four hours a day, constantly willing to help and to solve problems. 
Your complete dedication and commitment to research and to your people, and your 
modest personality are remarkable. You gained my deepest respect and admiration! 
I am deeply grateful to my direct supervisor dr. Juliette van den Dolder. Dear Juliette, 
you guided my first steps in research and helped me to develop my own ideas. It was 
not always easy for you, having in mind how stubborn I can be sometimes. However, 
you always encouraged me, and sometimes had even more confidence in me than I 
had in myself. Besides being my supervisor, you became also my friend. Thank you 
for your scientific and personal guidance, for your inspiring optimism, without which I 
wouldn’t have been able to succeed!
I would like to express my appreciation to my other supervisor, dr. Jeroen van den 
Beucken. Dear Jeroen, although you have joined me in my research during the last 
phase of my study, you have played an important part in it. Your expertise and detailed 
attention to every word and every concept contributed greatly to improve the quality of 
this thesis. I highly appreciate your willingness to help, and to constantly give the best 
and to expect the same from me in return. I hope that we will continue to work together 
in the same encouraging atmosphere. Thank you!
I would like to express my gratitude to Prof. dr. Nico Creugers. Dear Nico, it has been 
a great pleasure for me to work with you, both professionally and personally! Thank 
you for giving me a broad scientific view and making me think differently!
I would like to acknowledge all the people from the Animal Facility (CDL) Radboud 
University Nijmegen, who helped with my experiments. My special thanks go to Gert, 
Ilona, Debby and Brenda, without whom I wouldn’t have been able to carry out my 
animal studies.
I acknowledge Cees Verhagen from Sanquin Bloedbank, Nijmegen for providing me 
with human and goat PRP, and Dolf Lubbers, department of Hematology, UMCN, for 
counting the platelets.
Ik ben mijn collega’s van de Afdeling Biomaterialen en Parodontologie van het UMC 
St. Radboud zeer erkentelijk voor de geweldige tijd die ik op de afdeling mocht heb-
ben. Hartelijk dank dat jullie mij vanaf het eerste begin accepteerden als één van jullie. 
Ik heb me al die tijd onderdeel van jullie team gevoeld, ondanks het gegeven dat ik 
vaak kwam én ging. Met enkelen van jullie heb ik een diep gekoesterde vriendschap 
gesloten. Eens zei één van jullie mij dat ik als “half Nederlands” werd beschouwd, 
hetgeen mij bijzonder raakte. Ik voel me erg thuis in Nederland, Nijmegen en de afdel-
ing. Met naam en toenaam wil ik jullie bedanken voor de vriendschap, het gezelsc-
hap en de behulpzaamheid: Afsheen, Anja, Anne, Corrine, Daniel, Dennis, Dimitris, 
Esther, Fang Yang, Frank, George, Hongbing, Joop, Juliet, Jurgen, Kim, Lise, Manal, 
Marthijn, Mareijke, Meike, Natasja, Nelleke, Olga, Quinten, Ruud, Ruediger, Sander, 
Vincent, Walter, Weibo, Wouter, Yongang en Xuechao. Zeer in het bijzonder wil ik 
Esther en Sander, mijn paranimfen, bedanken. Veel dank voor jullie gezelschap en 
heerlijke gevoel voor humor, dat ik intens bewonder! Met de hulp ontvangen van Anja 
prijs ik me zeer gelukkig. Niet alleen in het laboratorium, maar ook in het dagelijkse 
leven en bij persoonlijke zaken was zij er altijd om naar me te luisteren en te helpen. 
Ook ben ik dank verschuldigd aan Natasja voor de vele uren die zij heeft besteed aan 
het prepareren van de histologische coupes. Speciale dank ook voor Vincent voor het 
uitvoeren van de micro-CT scans en voor de tekeningen die hij voor mij maakte.
A special gratitute to all the people from the department of Oral Function. During my 
research I had the chance to get to know you better and we have spent some un-
forgettable times together. Thank you Anneloes, Arie, Celeste, Chen, Dick, Toa, and 
Wietske in particular! 
Last, but not least I want to express my deepest gratitude to my whole family and 
especially to my husband, my son and my mother. Without their unconditional love, 
support and understanding through all these years, my PhD study wouldn’t have been 
possible. Мило семейство, много ви обичам всички, и се надявам, че в бъдеще 
сте мога да компенсирам времето, което сме прекарали разделени! 
Chapter  Acknowledgements
11 11
8 9
Chapter 12
Curriculum Vitae
0 
 
Adelina Stefanova Plachokova was born in Sofia, Bulgaria, 
on 9th of July 9. She attended the German gymnasium 
and simultaneously the English gymnasium in Sofia as a 
private student, and graduated with “cum laude” in 99. 
From 99 till 000 she studied Dentistry at the Medical 
University – Sofia, Faculty of Dental Medicine (Master de-
gree). During her study she won a DAAD (Deutsch Akade-
mischer Austausch Dienst) award and spent a month at the 
University of Essen in Germany. After graduation she
started a private dental practice in Sofia as a general practitioner. From 2001 till 2003 
she worked as an interpreter for the German journal “Quintessenz” in Bulgaria, trans-
lating articles from German into Bulgarian. Since 00 she has been employed as an 
Assistant Professor at the Department of Periodontology, Faculty of Dental Medicine 
- Sofia. The same year she was enrolled at the post-graduate programme in Periodon-
tology. In 00 she won a Huygens award and spent seven months at the department 
of Periodontology and Biomaterials, College of Dental Science, Radboud University 
Nijmegen Medical Center. During that time she started her PhD study in the department 
under the supervision of Prof. dr. John Jansen. 
Since 00 she has been married to Nikola Damyanov and has one son. 
Curriculum Vitae
 
List of publications related to the thesis
1. Plachokova AS, van den Dolder J, Stoelinga PJ, Jansen JA. The bone regenerative 
effect of platelet-rich plasma in combination with an osteoconductive material in rat 
cranial defects. Clin Oral Implants Res. 2006, 17:305-11. 
2. Plachokova AS, van den Dolder J, Stoelinga PJ, Jansen JA. Early effect of platelet-
rich plasma on bone healing in combination with an osteoconductive material in rat 
cranial defects. Clin Oral Implants Res. 2007;18: 244-51.
3. Plachokova AS, Link D, van den Dolder J, van den Beucken JJP, Jansen JA. Bone 
regenerative properties of injectable PLGA-CaP composite with TGF-ß1 in a rat aug-
mentation model. J Tissue Eng Regen Med. 2007, 1: 457-64. 
4. Plachokova AS, van den Dolder J,  Jansen JA. The bone-regenerative properties of 
Emdogain® adsorbed onto poly(d,l-lactic-coglycolic acid)/calcium phosphate compos-
ites in an ectopic and an orthotopic rat model. J Periodont Res. 2008, 43: 55-63.
5. Plachokova AS, Nikolidakis D, Mulder J, Jansen JA, Creugers NHJ. Effect of platelet-
rich plasma on bone regeneration in dentistry-a systematic review. Clin Oral Implants 
Res. 2008, 19: 539-45.
6. Plachokova AS, van den Dolder J, van den Beucken JJP, Jansen JA. Bone regenera-
tive properties of rat, goat and human PRP. Bone; submitted.
Congress presentations: 
1. Plachokova AS, van den Dolder J, Stoelinga PJ, Jansen JA. The bone regenera-
tive effect of platelet-rich plasma in combination with an osteoconductive mate-
rial in rat cranial defects, 8th Annual Tissue Engineering Society International (TESI) 
Conference&Exposition (October 22-25, 2005), Shanghai, China.
2. Plachokova AS, van den Dolder J, Jansen JA. The Bone Regenerative Properties 
of Emdogain®, IADR/AADR/CADR 85th General Session and Exhibition (March 21-24, 
2007), New Orleans, USA- finalist for Young Investigator’s Award in the Implantology 
Research Group.
3. Nikolidakis D, Plachokova AS, Jansen JA, Creugers NHJ. Effect of PRP on Alveolar 
Bone Regeneration: a Systematic Review, 42nd annual meeting of IADR-Continental 
European and Israeli Divisions (Sept 26-29, 2007), Thessaloniki, Greece.
4. Plachokova AS, van den Dolder J, van den Beucken JJP, Jansen JA. Bone regen-
erative properties of platelet-rich plasma, IADR/AADR/CADR 86th General Session and 
Exhibition (July 2-5, 2008) Toronto, Canada. 
Acknowledgements for the publication of the thesis:
Steunt orthopedische research
 
